{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:43:06Z","timestamp":1792788186459,"version":"4.5.0"},"reference-count":371,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Primary Research and Development Plan of Jiangsu Province","award":["BE2022840"],"award-info":[{"award-number":["BE2022840"]}]},{"name":"Shandong Provincial Laboratory Project","award":["SYS202202"],"award-info":[{"award-number":["SYS202202"]}]},{"name":"Research Project of Jinan Microecological Biomedicine Shandong Laboratory","award":["JNL-2025008B, JNL-2025009B, JNL-2025011B, JNL-2025010B, JNL 2025012B, and JNL-2023017D"],"award-info":[{"award-number":["JNL-2025008B, JNL-2025009B, JNL-2025011B, JNL-2025010B, JNL 2025012B, and JNL-2023017D"]}]},{"name":"Shandong Provincial Natural Science Foundation","award":["ZR2025MS1306"],"award-info":[{"award-number":["ZR2025MS1306"]}]},{"name":"Key R&D Program of Shandong Province","award":["2025CXPT176"],"award-info":[{"award-number":["2025CXPT176"]}]},{"name":"National Natural Science Foundation of China","award":["82272819 and 81972888"],"award-info":[{"award-number":["82272819 and 81972888"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Oncolytic viruses (OVs) represent a versatile platform for cancer immunotherapy, capable of selectively infecting and lysing tumor cells while triggering systemic antitumor immunity. However, their therapeutic efficacy remains limited by antiviral immunity, restricted intratumoral spread, and an immunosuppressive tumor microenvironment. This review highlights emerging strategies to potentiate OV efficacy through rational combination with complementary immunotherapies, including immune checkpoint inhibitors, adoptive cell therapies, cancer vaccines, and small-molecule immunomodulators. These synergistic interventions can remodel the tumor microenvironment, enhance immune cell infiltration and activation, reverse immunosuppressive feedback, promote immunogenic cell death, normalize the tumor vasculature, and modulate the gut microbiota, collectively amplifying OV replication and oncolytic potency. The integration of artificial intelligence and multiomics profiling further enables precise patient stratification and optimization of combination regimens. In parallel, advanced engineering strategies, such as arming OVs with immunomodulatory transgenes and mitigating host antiviral responses, further reinforce these effects. Together, these approaches illustrate how multimodal immunotherapy can overcome the intrinsic limitations of OVs, enabling durable antitumor immunity. This review underscores the central role of combination strategies in OV-based immuno-oncology and outlines future directions to accelerate their clinical translation.<\/jats:p>","DOI":"10.1186\/s40164-026-00805-0","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:01:44Z","timestamp":1783008104000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Leveraging multimodal cancer immunotherapy to amplify the efficacy of oncolytic viruses"],"prefix":"10.1186","volume":"15","author":[{"given":"Qiying","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louqian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingkai","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosong","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wujun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunping","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4753-2648","authenticated-orcid":false,"given":"Junhua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"805_CR1","doi-asserted-by":"crossref","unstructured":"Haux J. Infection and cancer. Lancet. 2001;358 (9276): 155\u20136.","DOI":"10.1016\/S0140-6736(01)05369-7"},{"issue":"24","key":"805_CR2","first-page":"e2313389","volume":"36","author":"J Jia","year":"2024","unstructured":"Jia J, Wang X, Lin X, Zhao YE. Microorganisms Adv Tumor Therapy Adv Mater. 2024;36(24):e2313389.","journal-title":"Microorganisms Adv Tumor Therapy Adv Mater"},{"key":"805_CR3","doi-asserted-by":"crossref","unstructured":"Russell SJ. Peng K W.Viruses as anticancer drugs. Trends Pharmacol Sci 2007;28 (7): 326\u201333.","DOI":"10.1016\/j.tips.2007.05.005"},{"key":"805_CR4","doi-asserted-by":"crossref","unstructured":"Lawler SE, Speranza MC, Cho CF, Chiocca EA. .Oncolytic Viruses in Cancer Treatment: A Review. JAMA Oncol. 2017;3 (6): 841\u20139.","DOI":"10.1001\/jamaoncol.2016.2064"},{"issue":"9","key":"805_CR5","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrd4663","volume":"14","author":"HL Kaufman","year":"2015","unstructured":"Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14(9):642\u201362.","journal-title":"Nat Rev Drug Discov"},{"key":"805_CR6","doi-asserted-by":"crossref","unstructured":"Musher BL, Rowinsky EK, Smaglo BG, Abidi W, Othman M, Patel K et al. LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1\/2 study.Lancet Oncol. 2024;25 (4): 488\u2013500.","DOI":"10.1016\/S1470-2045(24)00079-2"},{"issue":"7","key":"805_CR7","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1158\/1078-0432.CCR-24-2498","volume":"31","author":"EJ West","year":"2025","unstructured":"West EJ, Sadoun A, Bendjama K, Erbs P, Smolenschi C, Cassier PA, et al. A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer. Clin Cancer Res. 2025;31(7):1243\u201356.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"805_CR8","doi-asserted-by":"publisher","first-page":"e010543","DOI":"10.1136\/jitc-2024-010543","volume":"13","author":"Z Tan","year":"2025","unstructured":"Tan Z, Wu Y, Fan Z, Gao T, Ding S, Han L, et al., et al. Intratumoral oncolytic virus OH2 injection in patients with locally advanced or metastatic sarcoma: a phase 1\/2 trial. J Immunother Cancer. 2025;13(1):e010543.","journal-title":"J Immunother Cancer"},{"key":"805_CR9","unstructured":"Thorne SH, Hwang TH, Kirn DH. .Vaccinia virus and oncolytic virotherapy of cancer. Curr Opin Mol Ther 2005;7 (4): 359\u201365."},{"key":"805_CR10","doi-asserted-by":"crossref","unstructured":"Todo T. Oncolytic virus therapy using genetically engineered herpes simplex viruses. Front Biosci, 2008;13: 2060\u20134.","DOI":"10.2741\/2823"},{"key":"805_CR11","doi-asserted-by":"crossref","unstructured":"Ma R, Li Z, Chiocca EA, Caligiuri MA, Yu J. The emerging field of oncolytic virus-based cancer immunotherapy. Trends Cancer, 2023;9 (2): 122\u201339.","DOI":"10.1016\/j.trecan.2022.10.003"},{"key":"805_CR12","doi-asserted-by":"crossref","unstructured":"Lee WS, Lee SJ, Lee HJ, Yang H, Go EJ, Gansukh E et al. Oral reovirus reshapes the gut microbiome and enhances antitumor immunity in colon cancer. Nat Commun, 2024;15 (1): 9092.","DOI":"10.1038\/s41467-024-53347-6"},{"issue":"1","key":"805_CR13","doi-asserted-by":"publisher","first-page":"2377830","DOI":"10.1080\/2162402X.2024.2377830","volume":"13","author":"C Chatelain","year":"2024","unstructured":"Chatelain C, Berland L, Grard M, Jouand N, Fresquet J, Nader J, et al. Interplay between oncolytic measles virus, macrophages and cancer cells induces a proinflammatory tumor microenvironment. Oncoimmunology. 2024;13(1):2377830.","journal-title":"Oncoimmunology"},{"key":"805_CR14","doi-asserted-by":"crossref","unstructured":"Gong Y, Tang N, Liu P, Sun Y, Lu S, Liu W et al. Newcastle disease virus degrades SIRT3 via PINK1-PRKN-dependent mitophagy to reprogram energy metabolism in infected cells. Autophagy, 2022;18 (7): 1503\u201321.","DOI":"10.1080\/15548627.2021.1990515"},{"key":"805_CR15","doi-asserted-by":"crossref","unstructured":"Giedlin MA, Cook DN, Dubensky TW. Jr.Vesicular stomatitis virus: an exciting new therapeutic oncolytic virus candidate for cancer or just another chapter from Field\u2019s Virology? Cancer Cell, 2003;4 (4): 241\u20133.","DOI":"10.1016\/S1535-6108(03)00251-4"},{"issue":"24","key":"805_CR16","doi-asserted-by":"publisher","first-page":"15622","DOI":"10.3390\/ijms232415622","volume":"23","author":"K Lundstrom","year":"2022","unstructured":"Lundstrom K. Therapeutic applications for oncolytic self-replicating RNA viruses. Int J Mol Sci. 2022;23(24):15622.","journal-title":"Int J Mol Sci"},{"key":"805_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ejphar.2018.08.042","volume":"837","author":"P Alberts","year":"2018","unstructured":"Alberts P, Tilgase A, Rasa A, Bandere K, Venskus D. The advent of oncolytic virotherapy in oncology: The Rigvir\u00ae. story Eur J Pharmacol. 2018;837:117\u201326.","journal-title":"story Eur J Pharmacol"},{"issue":"2","key":"805_CR18","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2174\/1568009618666171129221503","volume":"18","author":"M Liang","year":"2018","unstructured":"Liang M. Oncorine, the World First Oncolytic Virus Medicine and its Update in China. Curr Cancer Drug Targets. 2018;18(2):171\u20136.","journal-title":"Curr Cancer Drug Targets"},{"key":"805_CR19","doi-asserted-by":"crossref","unstructured":"Poh AF. Oncolytic Viral Therapy for Melanoma. Cancer Discov, 2016;6 (1): 6.","DOI":"10.1158\/2159-8290.CD-NB2015-158"},{"key":"805_CR20","doi-asserted-by":"crossref","unstructured":"Frampton JE. .Teserpaturev\/G47\u2206: First Approval. BioDrugs. 2022;36 (5): 667\u201372.","DOI":"10.1007\/s40259-022-00553-7"},{"issue":"2","key":"805_CR21","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3892\/ijo.2018.4661","volume":"54","author":"V Schirrmacher","year":"2019","unstructured":"Schirrmacher V. From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review). Int J Oncol. 2019;54(2):407\u201319.","journal-title":"Int J Oncol"},{"key":"805_CR22","doi-asserted-by":"crossref","unstructured":"Toulmonde M, Guegan JP, Spalato-Ceruso M, Peyraud F, Kind M, Vanhersecke L et al. Reshaping the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: a phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamide. Mol Cancer, 2024;23 (1): 38.","DOI":"10.1186\/s12943-024-01946-8"},{"issue":"1","key":"805_CR23","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s12935-022-02585-z","volume":"22","author":"A Mardi","year":"2022","unstructured":"Mardi A, Shirokova AV, Mohammed RN, Keshavarz A, Zekiy AO, Thangavelu L, et al. Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction. Cancer Cell Int. 2022;22(1):168.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"805_CR24","doi-asserted-by":"publisher","first-page":"2490346","DOI":"10.1080\/2162402X.2025.2490346","volume":"14","author":"C Maresca","year":"2025","unstructured":"Maresca C, Franz\u00e8 E, Laudisi F, Colella M, Iannucci A, Frascatani R, et al. Smad7 is a negative regulator of immunogenic cell death in colorectal cancer. Oncoimmunology. 2025;14(1):2490346.","journal-title":"Oncoimmunology"},{"key":"805_CR25","doi-asserted-by":"crossref","unstructured":"Hong B, Sahu U, Mullarkey MP, Kaur B. Replication and spread of oncolytic herpes simplex virus in solid tumors. Viruses. 2022;14 (1): 118.","DOI":"10.3390\/v14010118"},{"key":"805_CR26","doi-asserted-by":"crossref","unstructured":"Depeaux K, Delgoffe GM. .Integrating innate and adaptive immunity in oncolytic virus therapy. Trends Cancer. 2024;10 (2): 135\u201346.","DOI":"10.1016\/j.trecan.2023.09.012"},{"issue":"12","key":"805_CR27","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.7150\/thno.83495","volume":"13","author":"S Liu","year":"2023","unstructured":"Liu S, Li F, Ma Q, Du M, Wang H, Zhu Y, et al. OX40L-Armed Oncolytic Virus Boosts T-cell Response and Remodels Tumor Microenvironment for Pancreatic Cancer Treatment. Theranostics. 2023;13(12):4016\u201329.","journal-title":"Theranostics"},{"key":"805_CR28","doi-asserted-by":"crossref","unstructured":"Roy DG, Geoffroy K, Marguerie M, Khan ST, Martin NT, Kmiecik J et al. Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination. Nat Commun 2021; 12 (1): 2626.","DOI":"10.1038\/s41467-021-22929-z"},{"key":"805_CR29","doi-asserted-by":"crossref","unstructured":"Zhou H, Astore C, Skolnick J. PHEVIR: an artificial intelligence algorithm that predicts the molecular role of pathogens in complex human diseases. Sci Rep. 2022;12 (1): 20889.","DOI":"10.1038\/s41598-022-25412-x"},{"key":"805_CR30","doi-asserted-by":"crossref","unstructured":"Workenhe ST, Mossman KL. .Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies. Mol Ther. 2014;22 (2): 251\u20136.","DOI":"10.1038\/mt.2013.220"},{"issue":"10","key":"805_CR31","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1158\/0008-5472.CAN-24-1959","volume":"85","author":"RA Hern\u00e1ndez-L\u00f3pez","year":"2025","unstructured":"Hern\u00e1ndez-L\u00f3pez RA, Kesti T, M\u00e4kel\u00e4 AR, Zhao Z, Yu W, Tonai Y, et al. Engineered SH3-Derived Sherpabodies Function as a Modular Platform for Targeted T-cell Immunotherapy. Cancer Res. 2025;85(10):1874\u201387.","journal-title":"Cancer Res"},{"key":"805_CR32","doi-asserted-by":"crossref","unstructured":"Melcher A, Parato K, Rooney CM, Bell JC. Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther. 2011;19 (6): 1008\u201316.","DOI":"10.1038\/mt.2011.65"},{"issue":"9","key":"805_CR33","doi-asserted-by":"publisher","first-page":"4865","DOI":"10.3390\/ijms23094865","volume":"23","author":"P Kalus","year":"2022","unstructured":"Kalus P, De Munck J, Vanbellingen S, Carreer L, Laeremans T, Broos K, et al. Oncolytic herpes simplex virus type 1 induces immunogenic cell death resulting in maturation of BDCA-1\u2009+\u2009myeloid dendritic cells. Int J Mol Sci. 2022;23(9):4865.","journal-title":"Int J Mol Sci"},{"key":"805_CR34","doi-asserted-by":"crossref","unstructured":"Puzanov I, Milhem MM, Minor D, Hamid O, Li A, Chen L et al. Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma. J Clin Oncol. 2016;34 (22): 2619\u201326.","DOI":"10.1200\/JCO.2016.67.1529"},{"issue":"1","key":"805_CR35","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12943-022-01657-y","volume":"21","author":"Y Wu","year":"2022","unstructured":"Wu Y, Yi M, Niu M, Mei Q, Wu K. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Mol Cancer. 2022;21(1):184.","journal-title":"Mol Cancer"},{"issue":"1","key":"805_CR36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40164-024-00505-7","volume":"13","author":"J Lu","year":"2024","unstructured":"Lu J, Luo Y, Rao D, Wang T, Lei Z, Chen X, et al. Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion. Exp Hematol Oncol. 2024;13(1):39.","journal-title":"Exp Hematol Oncol"},{"issue":"8","key":"805_CR37","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","volume":"28","author":"T Todo","year":"2022","unstructured":"Todo T, Ito H, Ino Y, Ohtsu H, Ota Y, Shibahara J, et al. Intratumoral oncolytic herpes virus G47\u2206 for residual or recurrent glioblastoma: a phase 2 trial. Nat Med. 2022;28(8):1630\u20139.","journal-title":"Nat Med"},{"key":"805_CR38","doi-asserted-by":"crossref","unstructured":"Rajwani J, Vishnevskiy D, Turk M, Naumenko V, Gafuik C, Kim DS et al. VSV(\u2206M51) drives CD8(+) T cell-mediated tumour regression through infection of both cancer and non-cancer cells. Nat Commun. 2024;15 (1): 9933.","DOI":"10.1038\/s41467-024-54111-6"},{"issue":"11","key":"805_CR39","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/s41577-023-00858-w","volume":"23","author":"R Burton","year":"2023","unstructured":"Burton R D. Antiviral neutralizing antibodies: from in vitro to in vivo activity. Nat Rev Immunol. 2023;23(11):720\u201334.","journal-title":"Nat Rev Immunol"},{"key":"805_CR40","doi-asserted-by":"crossref","unstructured":"Shin DH, Jiang H, Gillard AG, Kim D, Fan X, Singh SK et al. Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice. Mol Ther. 2024;32 (3): 722\u201333.","DOI":"10.1016\/j.ymthe.2024.01.035"},{"key":"805_CR41","doi-asserted-by":"crossref","unstructured":"Ricca JM, Oseledchyk A, Walther T, Liu C, Mangarin L, Merghoub T et al. Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy. Mol Ther. 2018;26 (4): 1008\u201319.","DOI":"10.1016\/j.ymthe.2018.01.019"},{"key":"805_CR42","doi-asserted-by":"crossref","unstructured":"Groeneveldt C, Van Den Ende J, Van Montfoort N. Preexisting immunity: Barrier or bridge to effective oncolytic virus therapy?Cytokine. Growth Factor Rev 2023;70: 1\u201312.","DOI":"10.1016\/j.cytogfr.2023.01.002"},{"key":"805_CR43","doi-asserted-by":"crossref","unstructured":"Ling AL, Solomon IH, Landivar AM, Nakashima H, Woods JK, Santos A et al. Clinical trial links oncolytic immunoactivation to survival in glioblastoma. Nature. 2023;623 (7985): 157\u201366.","DOI":"10.1038\/s41586-023-06623-2"},{"key":"805_CR44","doi-asserted-by":"crossref","unstructured":"Jayawardena N, Poirier JT, Burga LN, Bostina M. Virus-Receptor Interactions and Virus Neutralization: Insights for Oncolytic Virus Development. Oncolytic Virother. 2020;9: 1\u201315.","DOI":"10.2147\/OV.S186337"},{"key":"805_CR45","doi-asserted-by":"crossref","unstructured":"Mato-Berciano A, Morgado S, Maliandi MV, Farrera-Sal M, Gimenez-Alejandre M, Ginest\u00e0 MM et al. Oncolytic adenovirus with hyaluronidase activity that evades neutralizing antibodies: VCN-11. J Control Release. 2021;332: 517\u201328.","DOI":"10.1016\/j.jconrel.2021.02.035"},{"key":"805_CR46","doi-asserted-by":"crossref","unstructured":"Sanchez Gil J, Fudaba H, Wakimoto H. Chimeric oncolytic adenovirus to break away from neutralizing antibodies. Mol Ther. 2024;32 (4): 875\u20137.","DOI":"10.1016\/j.ymthe.2024.03.017"},{"key":"805_CR47","doi-asserted-by":"crossref","unstructured":"Nia GE, Nikpayam E, Farrokhi M, Bolhassani A, Meuwissen R. Advances in cell-based delivery of oncolytic viruses as therapy for lung cancer. Mol Ther Oncol 2024;32 (1): 200788.","DOI":"10.1016\/j.omton.2024.200788"},{"key":"805_CR48","doi-asserted-by":"crossref","unstructured":"Liang Y, Wang B, Chen Q, Fu X, Jiang C, Lin Z et al. Systemic delivery of glycosylated-PEG-masked oncolytic virus enhances targeting of antitumor immuno-virotherapy and modulates T and NK cell infiltration. Theranostics. 2023; 13 (15): 5452\u201368.","DOI":"10.7150\/thno.87498"},{"key":"805_CR49","doi-asserted-by":"crossref","unstructured":"Zhang W, Zhang J, Zhang J, Chu J, Zhang Z. Novel combination therapy using recombinant oncolytic adenovirus silk hydrogel and PD-L1 inhibitor for bladder cancer treatment. J Nanobiotechnology. 2024;22 (1): 638.","DOI":"10.1186\/s12951-024-02903-9"},{"key":"805_CR50","doi-asserted-by":"crossref","unstructured":"Zhao Y, Le TMD, Hong J, Jiao A, Yoon AR, Yun CO. Smart accumulating dual-targeting lipid envelopes equipping oncolytic adenovirus for enhancing cancer gene therapeutic efficacy. ACS Nano 2024;18 (41): 27869\u201390.","DOI":"10.1021\/acsnano.4c02165"},{"key":"805_CR51","doi-asserted-by":"crossref","unstructured":"Jia X, Wang L, Feng X, Liu W, Wang X, Li F et al. Cell Membrane-Coated Oncolytic Adenovirus for Targeted Treatment of Glioblastoma. Nano Lett. 2023;23 (23): 11120\u20138.","DOI":"10.1021\/acs.nanolett.3c03516"},{"key":"805_CR52","doi-asserted-by":"publisher","first-page":"574007","DOI":"10.3389\/fbioe.2020.574007","volume":"8","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Wu J, Zhang H, Wei J, Wu JE. Vesicles-Mimetic Encapsulation Improves Oncolytic Viro-Immunotherapy in Tumors With Low Coxsackie and Adenovirus Receptor. Front Bioeng Biotechnol. 2020;8:574007.","journal-title":"Front Bioeng Biotechnol"},{"key":"805_CR53","doi-asserted-by":"crossref","unstructured":"Chen Y, Chen X, Bao W, Liu G, Wei W, Ping Y. An oncolytic virus-T cell chimera for cancer immunotherapy. Nat Biotechnol. 2024;42 (12): 1876\u201387.","DOI":"10.1038\/s41587-023-02118-7"},{"issue":"2","key":"805_CR54","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11051-020-05134-9","volume":"23","author":"S Vupputuri","year":"2021","unstructured":"Vupputuri S, Tayebi L, Hikkaduwa Koralege RS, Nigatu A, Mozafari M, Mishra A, et al. Polyethylene glycol\u2013modified DOTAP:cholesterol\/adenovirus hybrid vectors have improved transduction efficiency and reduced immunogenicity. J Nanopart Res. 2021;23(2):37.","journal-title":"J Nanopart Res"},{"key":"805_CR55","doi-asserted-by":"crossref","unstructured":"Chen A, Zhang Y, Meng G, Jiang D, Zhang H, Zheng M et al. Oncolytic measles virus enhances antitumour responses of adoptive CD8(+)NKG2D(+) cells in hepatocellular carcinoma treatment. Sci Rep. 2017;7 (1): 5170.","DOI":"10.1038\/s41598-017-05500-z"},{"key":"805_CR56","doi-asserted-by":"crossref","unstructured":"Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci U S A. 2000;97 (23): 12846\u201351.","DOI":"10.1073\/pnas.97.23.12846"},{"issue":"13","key":"805_CR57","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1158\/1078-0432.CCR-24-3835","volume":"31","author":"TA Van Schaik","year":"2025","unstructured":"Van Schaik TA, Chen K-S, Kanaya N, Moreno-Lama L, Freeman NW, Wang M, et al. Antitumor Immunity Mediated by Engineered Stem Cells Exploiting TRAIL-Induced Cell Death and FLT3L Immunomodulation. Clin Cancer Res. 2025;31(13):2793\u2013813.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"805_CR58","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/cgt.2014.72","volume":"22","author":"RA Morshed","year":"2015","unstructured":"Morshed RA, Gutova M, Juliano J, Barish ME, Hawkins-Daarud A, Oganesyan D, et al. Analysis of glioblastoma tumor coverage by oncolytic virus-loaded neural stem cells using MRI-based tracking and histological reconstruction. Cancer Gene Ther. 2015;22(1):55\u201361.","journal-title":"Cancer Gene Ther"},{"key":"805_CR59","doi-asserted-by":"crossref","unstructured":"Fares J, Ahmed AU, Ulasov IV, Sonabend AM, Miska J, Lee-Chang C et al. Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial. Lancet Oncol. 2021;22 (8): 1103\u201314.","DOI":"10.1016\/S1470-2045(21)00245-X"},{"key":"805_CR60","doi-asserted-by":"crossref","unstructured":"Wang H, Borlongan M, Kaufman HL, Le U, Nauwynck HJ, Rabkin SD et al. Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy? J Immunother Cancer. 2024;12 (5): e008025.","DOI":"10.1136\/jitc-2023-008025"},{"key":"805_CR61","doi-asserted-by":"crossref","unstructured":"Webb MJ, Sangsuwannukul T, Van Vloten J, Evgin L, Kendall B, Tonne J et al. Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell response. Nat Commun. 2024;15 (1): 5442.","DOI":"10.1038\/s41467-024-49286-x"},{"issue":"1","key":"805_CR62","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41392-025-02511-5","volume":"10","author":"KY Shen","year":"2025","unstructured":"Shen KY, Yu SZ, Su YH, Xie SZ, Zhang C, Xu H, et al. Oncolytic adenovirus delivery of neoantigens sensitizes low-mutation tumors to anti-PD-1 therapy and prevents metastasis. Signal Transduct Target Ther. 2025;10(1):410.","journal-title":"Signal Transduct Target Ther"},{"key":"805_CR63","doi-asserted-by":"crossref","unstructured":"Jennings VA, Rumbold-Hall R, Migneco G, Barr T, Reilly K, Ingram N et al. Enhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprograming of the tumour microenvironment. Front Immunol. 2024;15: 1500570.","DOI":"10.3389\/fimmu.2024.1500570"},{"key":"805_CR64","doi-asserted-by":"crossref","unstructured":"Basnet S, Van Der Heijden M, Quixabeira DCA, Jirovec E, Gr\u00f6nberg-V\u00e4h\u00e4-Koskela S a, Clubb M et al. J H A,. Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokine. Mol Ther. 2024;32 (9): 3114\u20133127.","DOI":"10.1016\/j.ymthe.2024.06.029"},{"key":"805_CR65","doi-asserted-by":"crossref","unstructured":"Li X, Lu M, Yuan M, Ye J, Zhang W, Xu L et al. CXCL10-armed oncolytic adenovirus promotes tumor-infiltrating T-cell chemotaxis to enhance anti-PD-1 therapy. Oncoimmunology. 2022;11 (1): 2118210.","DOI":"10.1080\/2162402X.2022.2118210"},{"issue":"8","key":"805_CR66","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1073\/pnas.90.8.3539","volume":"90","author":"G Dranoff","year":"1993","unstructured":"Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A. 1993;90(8):3539\u201343.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"805_CR67","doi-asserted-by":"crossref","unstructured":"Kemp V, Van Den Wollenberg DJM, Camps MGM, Van Hall T, Kinderman P, Pronk-Van Montfoort N et al. Arming oncolytic reovirus with GM-CSF gene to enhance immunity. Cancer Gene Ther. 2019;26 (9\u201310): 268\u201381.","DOI":"10.1038\/s41417-018-0063-9"},{"key":"805_CR68","doi-asserted-by":"crossref","unstructured":"Hsieh CC, Hsieh MJ, Wang YH, Liao ZX. Macrophage Distribution Affected by Virus-Encoded Granulocyte Macrophage Colony Stimulating Factor Combined with Lactate Oxidase. ACS Omega. 2022;7 (27): 24020\u20136.","DOI":"10.1021\/acsomega.2c03213"},{"key":"805_CR69","doi-asserted-by":"crossref","unstructured":"Ponce S, Cedr\u00e9s S, Ricordel C, Isambert N, Viteri S, Herrera-Juarez M et al. ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment. J Immunother Cancer. 2023;11 (9): e007552.","DOI":"10.1136\/jitc-2023-007552"},{"issue":"1","key":"805_CR70","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40425-016-0121-5","volume":"4","author":"T Ranki","year":"2016","unstructured":"Ranki T, Pesonen S, Hemminki A, Partanen K, Kairemo K, Alanko T, et al. Phase I study with ONCOS-102 for the treatment of solid tumors\u2013an evaluation of clinical response and exploratory analyses of immune markers. J Immunother Cancer. 2016;4(1):17.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"805_CR71","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1158\/1078-0432.CCR-22-2046","volume":"29","author":"AN Shoushtari","year":"2023","unstructured":"Shoushtari AN, Olszanski AJ, Nyakas M, Hornyak TJ, Wolchok JD, Levitsky V, et al. Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti-PD-1-Resistant Advanced Melanoma. Clin Cancer Res. 2023;29(1):100\u20139.","journal-title":"Clin Cancer Res"},{"key":"805_CR72","doi-asserted-by":"crossref","unstructured":"Zhong L, Gan L, Wang B, Wu T, Yao F, Gong W et al. Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients. Cell. 2025;188 (4): 1119\u2013e113623.","DOI":"10.1016\/j.cell.2024.12.010"},{"key":"805_CR73","doi-asserted-by":"crossref","unstructured":"Faust Akl C, Andersen BM, Li Z, Giovannoni F, Diebold M, Sanmarco LM et al. Glioblastoma-instructed astrocytes suppress tumour-specific T cell immunity. Nature. 2025;643 (8070): 219\u201329.","DOI":"10.1038\/s41586-025-08997-x"},{"key":"805_CR74","doi-asserted-by":"crossref","unstructured":"Palanivelu L, Liu CH, Lin LT. .Immunogenic cell death: The cornerstone of oncolytic viro-immunotherapy. Front Immunol. 2022;13: 1038226.","DOI":"10.3389\/fimmu.2022.1038226"},{"issue":"12","key":"805_CR75","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.tips.2024.10.015","volume":"45","author":"Y Xiao","year":"2024","unstructured":"Xiao Y, Isaacs SN. .Poxvirus vaccines: the evolution of an 18th-century vaccine to the 21st century. Trends Pharmacol Sci. 2024;45(12):1086\u20138.","journal-title":"Trends Pharmacol Sci"},{"key":"805_CR76","doi-asserted-by":"crossref","unstructured":"Yu C, Wu Q, Xin J, Yu Q, Ma Z, Xue M et al. Designing a smallpox B-cell and T-cell multi-epitope subunit vaccine using a comprehensive immunoinformatics approach. Microbiol Spectr. 2024;12 (6): e0046524.","DOI":"10.1128\/spectrum.00465-24"},{"key":"805_CR77","doi-asserted-by":"crossref","unstructured":"Depeaux K, Gunn WG, Rivadeneira DB, Delgoffe GM. .Treatment with oncolytic vaccinia virus infects tumor-infiltrating regulatory and exhausted T cells. J Immunother Cancer. 2024;12 (8): e009062.","DOI":"10.1136\/jitc-2024-009062"},{"key":"805_CR78","doi-asserted-by":"crossref","unstructured":"Zuo S, Wei M, He B, Chen A, Wang S, Kong L et al. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT). EBioMedicine. 2021;64: 103240.","DOI":"10.1016\/j.ebiom.2021.103240"},{"key":"805_CR79","doi-asserted-by":"crossref","unstructured":"Ma J, Wu Y, Ma L, Yang X, Zhang T, Song G et al. A blueprint for tumor-infiltrating B cells across human cancers. Science. 2024;384 (6695): eadj4857.","DOI":"10.1126\/science.adj4857"},{"issue":"7","key":"805_CR80","doi-asserted-by":"publisher","first-page":"e1761","DOI":"10.1002\/ctm2.1761","volume":"14","author":"Z Li","year":"2024","unstructured":"Li Z, Lin A, Gao Z, Jiang A, Xiong M, Song J, et al. B-cell performance in chemotherapy: Unravelling the mystery of B-cell therapeutic potential. Clin Transl Med. 2024;14(7):e1761.","journal-title":"Clin Transl Med"},{"key":"805_CR81","doi-asserted-by":"crossref","unstructured":"Engelhard V, Conejo-Garcia JR, Ahmed R, Nelson BH, Willard-Gallo K, Bruno TC et al. B cells and cancer. Cancer Cell. 2021;39 (10): 1293\u20136.","DOI":"10.1016\/j.ccell.2021.09.007"},{"key":"805_CR82","doi-asserted-by":"crossref","unstructured":"Luo Y, Lin C, Zou Y, Ju F, Ren W, Lin Y et al. Tumor-targeting oncolytic virus elicits potent immunotherapeutic vaccine responses to tumor antigens. Oncoimmunology. 2020;9 (1): 1726168.","DOI":"10.1080\/2162402X.2020.1726168"},{"key":"805_CR83","doi-asserted-by":"crossref","unstructured":"Zheng S, Wang W, Shen L, Yao Y, Xia W, Ni C. Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies. Exp Hematol Oncol 2024;13 (1): 80.","DOI":"10.1186\/s40164-024-00543-1"},{"issue":"1","key":"805_CR84","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40164-024-00539-x","volume":"13","author":"Y Yin","year":"2024","unstructured":"Yin Y, Feng W, Chen J, Chen X, Wang G, Wang S, et al. Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside. Exp Hematol Oncol. 2024;13(1):72.","journal-title":"Exp Hematol Oncol"},{"issue":"7","key":"805_CR85","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1158\/1078-0432.CCR-21-2347","volume":"28","author":"Y Otani","year":"2022","unstructured":"Otani Y, Yoo JY, Lewis CT, Chao S, Swanner J, Shimizu T, et al. NOTCH-Induced MDSC Recruitment after oHSV Virotherapy in CNS Cancer Models Modulates Antitumor Immunotherapy. Clin Cancer Res. 2022;28(7):1460\u201373.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"805_CR86","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1172\/JCI45585","volume":"121","author":"N Woller","year":"2011","unstructured":"Woller N, Knocke S, Mundt B, G\u00fcrlevik E, Str\u00fcver N, Kloos A, et al. Virus-induced tumor inflammation facilitates effective DC cancer immunotherapy in a Treg-dependent manner in mice. J Clin Invest. 2011;121(7):2570\u201382.","journal-title":"J Clin Invest"},{"key":"805_CR87","doi-asserted-by":"crossref","unstructured":"Willmon C, Diaz RM, Wongthida P, Galivo F, Kottke T, Thompson J et al. Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide. Mol Ther. 2011;19 (1): 140\u20139.","DOI":"10.1038\/mt.2010.224"},{"key":"805_CR88","doi-asserted-by":"crossref","unstructured":"Aurelian L. Oncolytic viruses as immunotherapy: progress and remaining challenges. Onco Targets Ther. 2016;9: 2627\u201337.","DOI":"10.2147\/OTT.S63049"},{"issue":"7","key":"805_CR89","doi-asserted-by":"publisher","first-page":"e010514","DOI":"10.1136\/jitc-2024-010514","volume":"13","author":"Z Zhu","year":"2025","unstructured":"Zhu Z, Chen H, Feng C, Chen L, Ma C, Liu Z, et al. Specific inhibitor to KRASG12C induces tumor-specific immunity and synergizes with oncolytic virus for enhanced cancer immunotherapy. J Immunother Cancer. 2025;13(7):e010514.","journal-title":"J Immunother Cancer"},{"issue":"10","key":"805_CR90","doi-asserted-by":"publisher","first-page":"101751","DOI":"10.1016\/j.xcrm.2024.101751","volume":"5","author":"K Liu","year":"2024","unstructured":"Liu K, Kong L, Cui H, Zhang L, Xin Q, Zhuang Y, et al. Thymosin \u03b11 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy. Cell Rep Med. 2024;5(10):101751.","journal-title":"Cell Rep Med"},{"issue":"1","key":"805_CR91","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13046-025-03358-y","volume":"44","author":"S Wang","year":"2025","unstructured":"Wang S, Kong L, Wang L, Zhuang Y, Guo C, Zhang Y, et al. Viral expression of NE\/PPE enhances anti-colorectal cancer efficacy of oncolytic adenovirus by promoting TAM M1 polarization to reverse insufficient effector memory\/effector CD8(+) T cell infiltration.J. Exp Clin Cancer Res. 2025;44(1):97.","journal-title":"Exp Clin Cancer Res"},{"key":"805_CR92","doi-asserted-by":"crossref","unstructured":"Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell. 2011;146 (6): 873\u201387.","DOI":"10.1016\/j.cell.2011.08.039"},{"key":"805_CR93","doi-asserted-by":"crossref","unstructured":"Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307 (5706): 58\u201362.","DOI":"10.1126\/science.1104819"},{"key":"805_CR94","doi-asserted-by":"crossref","unstructured":"Ferrara N, Gerber HP, Lecouter J. The biology of VEGF and its receptors. Nat Med. 2003;9 (6): 669\u201376.","DOI":"10.1038\/nm0603-669"},{"key":"805_CR95","doi-asserted-by":"crossref","unstructured":"London NR, Whitehead KJ, Li DY. .Endogenous endothelial cell signaling systems maintain vascular stability. Angiogenesis, 2009;12 (2): 149\u201358.","DOI":"10.1007\/s10456-009-9130-z"},{"key":"805_CR96","doi-asserted-by":"crossref","unstructured":"Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol, 2013;31 (17): 2205\u201318.","DOI":"10.1200\/JCO.2012.46.3653"},{"key":"805_CR97","doi-asserted-by":"crossref","unstructured":"Matsuzaki H, Kai K, Komohara Y, Yano H, Pan C, Fujiwara Y et al. Abnormal Vessels Potentially Accelerate Glioblastoma Proliferation by Inducing the Protumor Activation of Macrophages. Cancer Sci, 2025;116 (4): 897\u2013909.","DOI":"10.1111\/cas.70014"},{"issue":"10","key":"805_CR98","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00535-024-02140-9","volume":"59","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Che N, Wang S, Meng J, Zhao N, Han J, et al. Nrf2\/ASPM axis regulated vasculogenic mimicry formation in hepatocellular carcinoma under hypoxia. J Gastroenterol. 2024;59(10):941\u201357.","journal-title":"J Gastroenterol"},{"issue":"5","key":"805_CR99","first-page":"1029","volume":"146","author":"HF Dvorak","year":"1995","unstructured":"Dvorak HF, Brown LF, Detmar M, Dvorak. A M.Vascular permeability factor\/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146(5):1029\u201339.","journal-title":"Am J Pathol"},{"key":"805_CR100","doi-asserted-by":"crossref","unstructured":"Shafqat A, Omer MH, Ahmed EN, Mushtaq A, Ijaz E, Ahmed Z et al. Reprogramming the immunosuppressive tumor microenvironment: exploiting angiogenesis and thrombosis to enhance immunotherapy.Front Immunol, 2023, 14: 1200941.","DOI":"10.3389\/fimmu.2023.1200941"},{"key":"805_CR101","doi-asserted-by":"crossref","unstructured":"Zhuang Y, Liu K, He Q, Gu X, Jiang C, Wu J. Hypoxia signaling in cancer: Implications for therapeutic interventions.MedComm (2020),2023;4 (1): e203.","DOI":"10.1002\/mco2.203"},{"key":"805_CR102","doi-asserted-by":"crossref","unstructured":"Wu Q, Jin Y, Li S, Guo X, Sun W, Liu J et al. Oncolytic Newcastle disease virus carrying the IL24 gene exerts antitumor effects by inhibiting tumor growth and vascular sprouting. Int Immunopharmacol, 2024;136: 112305.","DOI":"10.1016\/j.intimp.2024.112305"},{"key":"805_CR103","doi-asserted-by":"crossref","unstructured":"Breitbach CJ, De Silva NS, Falls TJ, Aladl U, Evgin L, Paterson J et al. Targeting tumor vasculature with an oncolytic virus. Mol Ther, 2011;19 (5): 886\u201394.","DOI":"10.1038\/mt.2011.26"},{"key":"805_CR104","doi-asserted-by":"crossref","unstructured":"Breitbach CJ, Arulanandam R, De Silva N, Thorne SH, Patt R, Daneshmand M et al. Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. Cancer Res, 2013;73 (4): 1265\u201375.","DOI":"10.1158\/0008-5472.CAN-12-2687"},{"key":"805_CR105","doi-asserted-by":"crossref","unstructured":"Huang Y, Kim BY, Chan CK, Hahn SM, Weissman IL, Jiang W. Improving immune\u2013vascular crosstalk for cancer immunotherapy. Nat Rev Immunol 2018;18 (3): 195\u2013203.","DOI":"10.1038\/nri.2017.145"},{"key":"805_CR106","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.omto.2021.12.016","volume":"24","author":"M Inoue","year":"2022","unstructured":"Inoue M, Kim M, Inoue T, Tait M, Byrne T, Nitschk\u00e9 M, et al. Oncolytic vaccinia virus injected intravenously sensitizes pancreatic neuroendocrine tumors and metastases to immune checkpoint blockade. Mol Ther Oncolytics. 2022;24:299\u2013318.","journal-title":"Mol Ther Oncolytics"},{"key":"805_CR107","doi-asserted-by":"crossref","unstructured":"He T, Hao Z, Lin M, Xin Z, Chen Y, Ouyang W et al. Oncolytic adenovirus promotes vascular normalization and nonclassical tertiary lymphoid structure formation through STING-mediated DC activation.Oncoimmunology,2022, 11 (1): 2093054.","DOI":"10.1080\/2162402X.2022.2093054"},{"key":"805_CR108","doi-asserted-by":"crossref","unstructured":"Yi J, Quji S, Guo L, Chai Z, Kong X, Meng JJ. C I.Exploring novel strategies of oncolytic viruses and gut microbiota to enhance CAR-T cell therapy for colorectal cancer.Cell Immunol,2025, 417: 105026.","DOI":"10.1016\/j.cellimm.2025.105026"},{"key":"805_CR109","doi-asserted-by":"crossref","unstructured":"Tripodi L, Feola S, Granata I, Whalley T, Passariello M, Capasso C et al. Bifidobacterium affects antitumor efficacy of oncolytic adenovirus in a mouse model of melanoma.iScience,2023, 26 (10): 107668.","DOI":"10.1016\/j.isci.2023.107668"},{"key":"805_CR110","doi-asserted-by":"crossref","unstructured":"Yi J, Lin P, Li Q, Zhang A. Kong X.A new strategy for treating colorectal cancer: Regulating the influence of intestinal flora and oncolytic virus on interferon.Mol Ther Oncolytics,2023, 30: 254\u201374.","DOI":"10.1016\/j.omto.2023.08.010"},{"key":"805_CR111","doi-asserted-by":"crossref","unstructured":"Zhang J, Yang J, Luo J, Wu W, Luo H, Wei W et al. Lactobacillus acidophilus potentiates oncolytic virotherapy through modulating gut microbiota homeostasis in hepatocellular carcinoma.Nat Commun,2025, 16 (1): 3315.","DOI":"10.1038\/s41467-025-58407-z"},{"key":"805_CR112","doi-asserted-by":"crossref","unstructured":"Chen X, Wang G, Qin L, Hu B, Li J. Intestinal Microbiota Modulates the Antitumor Effect of Oncolytic Virus Vaccines in Colorectal Cancer.Dig Dis Sci,2024, 69 (4): 1228\u201341.","DOI":"10.1007\/s10620-024-08346-4"},{"key":"805_CR113","doi-asserted-by":"crossref","unstructured":"Topol EJ. High-performance medicine: the convergence of human and artificial intelligence.Nat Med,2019, 25 (1): 44\u201356.","DOI":"10.1038\/s41591-018-0300-7"},{"key":"805_CR114","doi-asserted-by":"crossref","unstructured":"Esteva A, Robicquet A, Ramsundar B, Kuleshov V, Depristo M, Chou K et al. A guide to deep learning in healthcare.Nat Med,2019, 25 (1): 24\u201329.","DOI":"10.1038\/s41591-018-0316-z"},{"key":"805_CR115","doi-asserted-by":"crossref","unstructured":"Kourou K, Exarchos TP, Exarchos KP, Karamouzis MV. Fotiadis D I.Machine learning applications in cancer prognosis and prediction. Comput Struct Biotechnol J 2015, 13: 8\u201317.","DOI":"10.1016\/j.csbj.2014.11.005"},{"key":"805_CR116","doi-asserted-by":"crossref","unstructured":"Athisayamani S, Singh ST, Hwang AR, Joshi JY. G P.A novel double machine learning approach for detecting early breast cancer using advanced feature selection and dimensionality reduction techniques.Sci Rep,2025, 15 (1): 22971.","DOI":"10.1038\/s41598-025-06426-7"},{"key":"805_CR117","unstructured":"Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E et al. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.Cell,2018, 173 (2): 291\u2013e3046."},{"key":"805_CR118","doi-asserted-by":"crossref","unstructured":"Zhou J, Troyanskaya OG. Predicting effects of noncoding variants with deep learning-based sequence model.Nat Methods,2015, 12 (10): 931\u20134.","DOI":"10.1038\/nmeth.3547"},{"issue":"7","key":"805_CR119","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41576-019-0122-6","volume":"20","author":"G Eraslan","year":"2019","unstructured":"Eraslan G, Avsec \u017d, Gagneur J, Theis FJ. .Deep learning: new computational modelling techniques for genomics. Nat Rev Genet. 2019;20(7):389\u2013403.","journal-title":"Nat Rev Genet"},{"key":"805_CR120","doi-asserted-by":"publisher","first-page":"1675969","DOI":"10.3389\/frai.2025.1675969","volume":"8","author":"O Nave","year":"2025","unstructured":"Nave O, Barasheshet P. Artificial intelligence analysis applied to the treatment of granulosa cell tumors of the ovary. Front Artif Intell. 2025;8:1675969.","journal-title":"Front Artif Intell"},{"key":"805_CR121","doi-asserted-by":"crossref","unstructured":"Barab\u00e1si AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet 2011, 12 (1): 56\u201368.","DOI":"10.1038\/nrg2918"},{"key":"805_CR122","doi-asserted-by":"crossref","unstructured":"Sun Y, Huang Z-L, Chen W-X, Zhang Y-F, Lei H-T, Huang Q-J et al. GateView: A Multi-Omics Platform for Gene Feature Analysis of Virus Receptors within Human Normal Tissues and Tumors.Biomolecules,2024, 14 (5): 516.","DOI":"10.3390\/biom14050516"},{"key":"805_CR123","doi-asserted-by":"crossref","unstructured":"Badhan PK, Kaur M, Sood P, Gupta R. Real-Time Predictive Analytics for Oncolytic Virus Replication and Tumor Lysis Using Machine Learning,Applications of Nanomaterials for Oncology. IGI Global Scientific Publishing; 2026. pp. 231\u201358.","DOI":"10.4018\/979-8-3373-3765-4.ch008"},{"key":"805_CR124","doi-asserted-by":"publisher","first-page":"100258","DOI":"10.1016\/j.insi.2026.100258","volume":"2","author":"A Uthamacumaran","year":"2026","unstructured":"Uthamacumaran A, Kiyokawa J. Wakimoto H.AI-driven hybrid ecological model for predicting oncolytic viral therapy dynamics. Silico Res Biomed. 2026;2:100258.","journal-title":"Silico Res Biomed"},{"key":"805_CR125","doi-asserted-by":"crossref","unstructured":"Nielsen Aa, K, Der BS, Shin J, Vaidyanathan P, Paralanov V, Strychalski EA et al. Genetic circuit design automation.Science,2016, 352 (6281): aac7341.","DOI":"10.1126\/science.aac7341"},{"issue":"7","key":"805_CR126","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1158\/2326-6066.CIR-24-1270","volume":"13","author":"L Huang","year":"2025","unstructured":"Huang L, Wu X, You J, Jin Z, He W, Sun J, et al. Artificial intelligence can predict personalized immunotherapy outcomes in cancer. Cancer Immunol Res. 2025;13(7):964\u201377.","journal-title":"Cancer Immunol Res"},{"key":"805_CR127","doi-asserted-by":"crossref","unstructured":"Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G et al. Applications of machine learning in drug discovery and development.Nature reviews Drug discovery,2019, 18 (6): 463\u201377.","DOI":"10.1038\/s41573-019-0024-5"},{"key":"805_CR128","doi-asserted-by":"crossref","unstructured":"Topalian SL, Taube JM, Anders RA, Pardoll DM. .Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 2016, 16 (5): 275\u201387.","DOI":"10.1038\/nrc.2016.36"},{"key":"805_CR129","doi-asserted-by":"crossref","unstructured":"Aliazis K, Christofides A, Shah R, Yeo YY, Jiang S, Charest A et al. The tumor microenvironment\u2019s role in the response to immune checkpoint blockade.Nat Cancer,2025, 6 (6): 924\u201337.","DOI":"10.1038\/s43018-025-00986-3"},{"key":"805_CR130","doi-asserted-by":"crossref","unstructured":"Zhong C, Wang L, Liu Y, Wang X, Xia Z, Li Y et al. PSGL-1 is a phagocytosis checkpoint that enables tumor escape from macrophage clearance.Sci Immunol,2025, 10 (108): eadn4302.","DOI":"10.1126\/sciimmunol.adn4302"},{"key":"805_CR131","doi-asserted-by":"crossref","unstructured":"De Martin E, Fulgenzi C a, Celsa M, Laurent-Bellue C, Torkpour A, Lombardi A. P, Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events.Gut,2025, 74 (7): 1165\u201377.","DOI":"10.1136\/gutjnl-2024-332125"},{"key":"805_CR132","doi-asserted-by":"crossref","unstructured":"Hanahan D, Weinberg RA. .Hallmarks of cancer: the next generation.Cell,2011, 144 (5): 646\u201374.","DOI":"10.1016\/j.cell.2011.02.013"},{"key":"805_CR133","doi-asserted-by":"crossref","unstructured":"Lin A, Ye P, Li Z, Jiang A, Liu Z, Cheng Q et al. Natural Killer Cell Immune Checkpoints and Their Therapeutic Targeting in Cancer Treatment.Research (Wash D C),2025, 8: 0723.","DOI":"10.34133\/research.0723"},{"key":"805_CR134","doi-asserted-by":"crossref","unstructured":"Lim JX, Mctaggart T, Jung SK, Smith KJ, Hulme G, Laba S et al. PD-1 receptor deficiency enhances CD30\u2009+\u2009Treg cell function in melanoma.Nat Immunol,2025, 26 (7): 1074\u201386.","DOI":"10.1038\/s41590-025-02172-0"},{"key":"805_CR135","doi-asserted-by":"crossref","unstructured":"Chen L, Flies DB. .Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 2013, 13 (4): 227\u201342.","DOI":"10.1038\/nri3405"},{"key":"805_CR136","doi-asserted-by":"crossref","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012, 12 (4): 252\u201364.","DOI":"10.1038\/nrc3239"},{"issue":"8","key":"805_CR137","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019day S J, Mcdermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323.","journal-title":"N Engl J Med"},{"issue":"26","key":"805_CR138","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.N. Engl J Med. 2012;366(26):2455\u201365.","journal-title":"Engl J Med"},{"key":"805_CR139","doi-asserted-by":"crossref","unstructured":"Anderson AC, Joller N, Kuchroo VK. Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.Immunity,2016, 44 (5): 989\u20131004.","DOI":"10.1016\/j.immuni.2016.05.001"},{"key":"805_CR140","doi-asserted-by":"crossref","unstructured":"Lines JL, Pantazi E, Mak J, Sempere LF, Wang L, O\u2019connell S et al. VISTA is an immune checkpoint molecule for human T cells.Cancer Res,2014, 74 (7): 1924\u201332.","DOI":"10.1158\/0008-5472.CAN-13-1504"},{"key":"805_CR141","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/978-0-387-89520-8_11","volume":"647","author":"G Nocentini","year":"2009","unstructured":"Nocentini G, Riccardi CGITR. : a modulator of immune response and inflammation. Adv Exp Med Biol. 2009;647:156\u201373.","journal-title":"Adv Exp Med Biol"},{"key":"805_CR142","doi-asserted-by":"crossref","unstructured":"Sedy JR, Gavrieli M, Potter KG, Hurchla MA, Lindsley RC, Hildner K et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator.Nat Immunol,2005, 6 (1): 90\u20138.","DOI":"10.1038\/ni1144"},{"key":"805_CR143","doi-asserted-by":"crossref","unstructured":"Ribas A, Dummer R, Puzanov I, Vanderwalde A, Andtbacka RHI, Michielin O et al. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.Cell,2017, 170 (6): 1109\u2013e111910.","DOI":"10.1016\/j.cell.2017.08.027"},{"key":"805_CR144","doi-asserted-by":"crossref","unstructured":"Osaki M, Sakaguchi S. Soluble CTLA-4 regulates immune homeostasis and promotes resolution of inflammation by suppressing type 1 but allowing type 2 immunity.Immunity,2025, 58 (4): 889\u2013908. e13.","DOI":"10.1016\/j.immuni.2025.03.004"},{"key":"805_CR145","doi-asserted-by":"crossref","unstructured":"Arias-Badia M, Pai C-CS, Lwin YM, Chen P, Srinath A, Tanaka M et al. Impact of tumor localization on antitumor immunity with conditionally activated CTLA-4 blockade.J Immunother Cancer,2025, 13 (4): e010566.","DOI":"10.1136\/jitc-2024-010566"},{"key":"805_CR146","doi-asserted-by":"crossref","unstructured":"Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z et al. CTLA-4 control over Foxp3\u2009+\u2009regulatory T cell function.Science,2008, 322 (5899): 271\u20135.","DOI":"10.1126\/science.1160062"},{"key":"805_CR147","doi-asserted-by":"crossref","unstructured":"Krummel MF, Allison JP. .CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.J Exp Med,1995, 182 (2): 459\u201365.","DOI":"10.1084\/jem.182.2.459"},{"key":"805_CR148","doi-asserted-by":"crossref","unstructured":"Leach DR, Krummel MF, Allison JP. .Enhancement of antitumor immunity by CTLA-4 blockade.Science,1996, 271 (5256): 1734\u20136.","DOI":"10.1126\/science.271.5256.1734"},{"key":"805_CR149","doi-asserted-by":"crossref","unstructured":"Jamison BL, Lawrance M, Wang CJ, Deberg HA, Ziegler LJ, Sansom DM et al. An IL-2 mutein increases regulatory T cell suppression of dendritic cells via IL-10 and CTLA-4 to promote T cell anergy.Cell Rep,2024, 43 (11): 114938.","DOI":"10.1016\/j.celrep.2024.114938"},{"key":"805_CR150","doi-asserted-by":"crossref","unstructured":"Ju F, Luo Y, Lin C, Jia X, Xu Z, Tian R et al. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade.J Immunother Cancer,2022, 10 (6): e004762.","DOI":"10.1136\/jitc-2022-004762"},{"key":"805_CR151","doi-asserted-by":"crossref","unstructured":"Russell L, Peng KW, Russell SJ, Diaz RMO. Viruses: Priming Time for Cancer Immunotherapy.BioDrugs,2019, 33 (5): 485\u2013501.","DOI":"10.1007\/s40259-019-00367-0"},{"key":"805_CR152","doi-asserted-by":"crossref","unstructured":"Dias JD, Hemminki O, Diaconu I, Hirvinen M, Bonetti A, Guse K et al. Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4.Gene Ther,2012, 19 (10): 988\u201398.","DOI":"10.1038\/gt.2011.176"},{"issue":"16suppl","key":"805_CR153","doi-asserted-by":"publisher","first-page":"TPS2704","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS2704","volume":"40","author":"KJ Harrington","year":"2022","unstructured":"Harrington KJ, Sacco JJ, Olsson-Brown AC, Chan TY, Nenclares P, Leslie I, et al. A phase 1 trial of RP2, a first-in-class, enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody as a single agent and combined with nivolumab in patients with advanced solid tumors. J Clin Oncol. 2022;40(16suppl):TPS2704\u20132704.","journal-title":"J Clin Oncol"},{"key":"805_CR154","doi-asserted-by":"crossref","unstructured":"Chiu M, Armstrong EJL, Jennings V, Foo S, Crespo-Rodriguez E, Bozhanova G et al. Combination therapy with oncolytic viruses and immune checkpoint inhibitors.Expert Opin Biol Ther,2020, 20 (6): 635\u201352.","DOI":"10.1080\/14712598.2020.1729351"},{"key":"805_CR155","doi-asserted-by":"crossref","unstructured":"Chesney JA, Puzanov I, Collichio FA, Singh P, Milhem MM, Glaspy J et al. Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial.J Immunother Cancer,2023, 11 (5): e006270.","DOI":"10.1136\/jitc-2022-006270"},{"key":"805_CR156","doi-asserted-by":"crossref","unstructured":"Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.Embo j,1992, 11 (11): 3887\u201395.","DOI":"10.1002\/j.1460-2075.1992.tb05481.x"},{"key":"805_CR157","doi-asserted-by":"crossref","unstructured":"Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo. T.PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine.Proc Natl Acad Sci U S A,2001, 98 (24): 13866\u201371.","DOI":"10.1073\/pnas.231486598"},{"key":"805_CR158","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ. Sharpe A H.PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677\u2013704.","journal-title":"Annu Rev Immunol"},{"key":"805_CR159","doi-asserted-by":"crossref","unstructured":"Wang X, Wang G, Wang Z, Liu B, Han N, Li J et al. PD-1-expressing B cells suppress CD4(+) and CD8(+) T cells via PD-1\/PD-L1-dependent pathway.Mol Immunol,2019, 109: 20\u20136.","DOI":"10.1016\/j.molimm.2019.02.009"},{"key":"805_CR160","doi-asserted-by":"crossref","unstructured":"Mariotti FR, Petrini S, Ingegnere T, Tumino N, Besi F, Scordamaglia F et al. PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression.Oncoimmunology,2019, 8 (3): 1557030.","DOI":"10.1080\/2162402X.2018.1557030"},{"key":"805_CR161","doi-asserted-by":"crossref","unstructured":"Topalian SL, Drake CG, Pardoll DM. .Immune checkpoint blockade: a common denominator approach to cancer therapy.Cancer Cell,2015, 27 (4): 450\u201361.","DOI":"10.1016\/j.ccell.2015.03.001"},{"key":"805_CR162","doi-asserted-by":"crossref","unstructured":"Sun Y, Yang J, Chen Y, Guo Y, Xiong J, Guo X et al. PD-L2 Expression in Breast Cancer Promotes Tumor Development and Progression.J Immunol Res,2024, 2024: 3145695.","DOI":"10.1155\/2024\/3145695"},{"key":"805_CR163","doi-asserted-by":"crossref","unstructured":"Lin X, Lin K, Lin C, Liu T, Ba M, Tang Y et al. Prognostic and clinicopathological value of PD-L2 in lung cancer: A meta-analysis.Int Immunopharmacol,2021, 91: 107280.","DOI":"10.1016\/j.intimp.2020.107280"},{"key":"805_CR164","doi-asserted-by":"crossref","unstructured":"Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 2005, 25 (21): 9543\u201353.","DOI":"10.1128\/MCB.25.21.9543-9553.2005"},{"key":"805_CR165","doi-asserted-by":"crossref","unstructured":"He X, Xu C. Immune checkpoint signaling and cancer immunotherapy.Cell Res,2020, 30 (8): 660\u20139.","DOI":"10.1038\/s41422-020-0343-4"},{"issue":"4","key":"805_CR166","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1805131","volume":"379","author":"MR Migden","year":"2018","unstructured":"Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018;379(4):341\u201351.","journal-title":"N Engl J Med"},{"issue":"13","key":"805_CR167","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1056\/NEJMc1509660","volume":"373","author":"MEC Valsecchi","year":"2015","unstructured":"Valsecchi MEC. Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(13):1270.","journal-title":"N Engl J Med"},{"key":"805_CR168","doi-asserted-by":"crossref","unstructured":"Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D\u2019angelo SP et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.Lancet Oncol,2016, 17 (10): 1374\u201385.","DOI":"10.1016\/S1470-2045(16)30364-3"},{"issue":"20","key":"805_CR169","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377(20):1919\u201329.","journal-title":"N Engl J Med"},{"issue":"19","key":"805_CR170","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375(19):1823\u201333.","journal-title":"N Engl J Med"},{"key":"805_CR171","doi-asserted-by":"crossref","unstructured":"Sharma P, Siddiqui BA, Anandhan S, Yadav SS, Subudhi SK, Gao J et al. The Next Decade of Immune Checkpoint Therapy.Cancer Discov,2021, 11 (4): 838\u201357.","DOI":"10.1158\/2159-8290.CD-20-1680"},{"issue":"1","key":"805_CR172","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12935-024-03238-z","volume":"24","author":"JS Park","year":"2024","unstructured":"Park JS, Lee ME, Kim J, Oh K, Lee N, Jung M, et al. PD-1 inhibitor plus oncolytic vaccinia virus is a safe and effective treatment option for metastatic renal cell carcinoma. Cancer Cell Int. 2024;24(1):50.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"805_CR173","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40164-025-00611-0","volume":"14","author":"Y Zhu","year":"2025","unstructured":"Zhu Y, Zhang X, Jin J, Wang X, Liu Y, Gao J, et al. Engineered oncolytic virus coated with anti-PD-1 and alendronate for ameliorating intratumoral T cell hypofunction. Exp Hematol Oncol. 2025;14(1):16.","journal-title":"Exp Hematol Oncol"},{"key":"805_CR174","doi-asserted-by":"crossref","unstructured":"Sun Q, Hong Z, Zhang C, Wang L, Han Z. Ma D.Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. Signal Transduct Target Ther 2023, 8 (1): 320.","DOI":"10.1038\/s41392-023-01522-4"},{"key":"805_CR175","doi-asserted-by":"publisher","first-page":"114120","DOI":"10.1016\/j.ejca.2024.114120","volume":"207","author":"C Robert","year":"2024","unstructured":"Robert C, Gastman B, Gogas H, Rutkowski P, Long GV, Chaney MF, et al. Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti-PD-1 therapy: MASTERKEY-115. Eur J Cancer. 2024;207:114120.","journal-title":"Eur J Cancer"},{"key":"805_CR176","doi-asserted-by":"crossref","unstructured":"Zhu L, Huang J, Zhang S, Cai Q, Guo X, Liu B et al. oHSV2-mGM repolarizes TAMs and cooperates with \u03b1PD1 to reprogram the immune microenvironment of residual cancer after radiofrequency ablation.Biomed Pharmacother,2024, 178: 117060.","DOI":"10.1016\/j.biopha.2024.117060"},{"key":"805_CR177","doi-asserted-by":"crossref","unstructured":"Wang X, Cui C, Yin S, Cong Y, Lian B, Li C et al. Axitinib in combination with anti\u2013PD-1 ab (pucotenlimab) plus intra-hepatic injection of oncolytic virus (OH2), in patients with mucosal melanoma and liver metastasis: An open-label phase I trial.J Clin Oncol,2024, 42 (16_suppl): e21524\u201321524.","DOI":"10.1200\/JCO.2024.42.16_suppl.e21524"},{"issue":"4","key":"805_CR178","doi-asserted-by":"publisher","first-page":"e014530","DOI":"10.1136\/jitc-2025-014530","volume":"14","author":"A Yang","year":"2026","unstructured":"Yang A, Zhang Z, Park A, a-O, Chaurasiya S, a-O, Kim SI, Lu J, et al. Intraperitoneal CF33-hNIS combined with PD-L1 blockade eradicates gastric cancer peritoneal metastases and prevents recurrence via durable T cell memory. J Immunother Cancer. 2026;14(4):e014530.","journal-title":"J Immunother Cancer"},{"key":"805_CR179","doi-asserted-by":"crossref","unstructured":"Chouljenko DV, Ding J, Lee IF, Murad YM, Bu X, Liu G et al. Induction of Durable Antitumor Response by a Novel Oncolytic Herpesvirus Expressing Multiple Immunomodulatory Transgenes.Biomedicines,2020, 8 (11): 484.","DOI":"10.3390\/biomedicines8110484"},{"key":"805_CR180","doi-asserted-by":"crossref","unstructured":"Shen Y, Bai X, Zhang Q, Liang X, Jin X, Zhao Z et al. Oncolytic virus VG161 in refractory hepatocellular carcinoma.Nature,2025, 641 (8062): 503\u201311.","DOI":"10.1038\/s41586-025-08717-5"},{"key":"805_CR181","doi-asserted-by":"crossref","unstructured":"Arafat Hossain. M.A comprehensive review of immune checkpoint inhibitors for cancer treatment.Int Immunopharmacol,2024, 143 (Pt 2): 113365.","DOI":"10.1016\/j.intimp.2024.113365"},{"key":"805_CR182","doi-asserted-by":"crossref","unstructured":"Xia L, Liu J-Y, Yu C, Lin H-W, Hu Y-H, Hu G-S et al. PILR\u03b1 on tumor cells interacts with the T cell surface protein CD99 to suppress antitumor immunity.Nature Cancer,2025, 6 (7): 1184\u2013201.","DOI":"10.1038\/s43018-025-00958-7"},{"key":"805_CR183","doi-asserted-by":"crossref","unstructured":"Wang SL, Chan TA. .Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy.Cancer Cell,2025, 43 (4): 641\u201364.","DOI":"10.1016\/j.ccell.2025.03.006"},{"issue":"7","key":"805_CR184","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41568-018-0009-4","volume":"18","author":"K Twumasi-Boateng","year":"2018","unstructured":"Twumasi-Boateng K, Pettigrew JL, Kwok YYE, Bell JC. Nelson B H.Oncolytic viruses as engineering platforms for combination immunotherapy. Nat Rev Cancer. 2018;18(7):419\u201332.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"805_CR185","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s40164-025-00696-7","volume":"14","author":"Z Qi","year":"2025","unstructured":"Qi Z, Hu S, Zhao J, Xu X, Huang A, Qin Y, et al. CD47 antibody-armed oncolytic adenovirus promotes chimeric antigen receptor macrophage phagocytosis and antitumor immunity. Exp Hematol Oncol. 2025;14(1):106.","journal-title":"Exp Hematol Oncol"},{"key":"805_CR186","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.omto.2020.11.001","volume":"20","author":"H Zhang","year":"2021","unstructured":"Zhang H, Zhang Y, Dong J, Li B, Xu C, Wei M, et al. Recombinant oncolytic adenovirus expressing a soluble PVR elicits long-term antitumor immune surveillance. Mol Ther Oncolytics. 2021;20:12\u201322.","journal-title":"Mol Ther Oncolytics"},{"key":"805_CR187","doi-asserted-by":"crossref","unstructured":"Zhang H, Zhang Y, Dong J, Zuo S, Meng G, Wu J et al. Recombinant adenovirus expressing the fusion protein PD1PVR improves CD8(+) T cell-mediated antitumor efficacy with long-term tumor-specific immune surveillance in hepatocellular carcinoma.Cell Oncol (Dordr),2021, 44 (6): 1243\u201355.","DOI":"10.1007\/s13402-021-00633-w"},{"key":"805_CR188","doi-asserted-by":"crossref","unstructured":"Rahman MM, Mcfadden G. Oncolytic virotherapy with myxoma virus. J Clin Med 2020, 9 (1): 171.","DOI":"10.3390\/jcm9010171"},{"key":"805_CR189","doi-asserted-by":"crossref","unstructured":"Gowan CC, Bartee MY, Flores E, Aksoy BA, Templeton C, Baillie K et al. The Combination of TIM3-Based Checkpoint Blockade and Oncolytic Virotherapy Regresses Established Solid Tumors.J Immunother,2023, 46 (1): 1\u20134.","DOI":"10.1097\/CJI.0000000000000444"},{"key":"805_CR190","doi-asserted-by":"crossref","unstructured":"Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: A new era of cancer treatment at dawn.Cancer Sci,2016, 107 (10): 1373\u20139.","DOI":"10.1111\/cas.13027"},{"issue":"14","key":"805_CR191","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-15-2428","volume":"22","author":"E Picarda","year":"2016","unstructured":"Picarda E, Ohaegbulam KC, Zang XM, Pathways. Targeting B7-H3 (CD276) for Human Cancer Immunotherapy. Clin Cancer Res. 2016;22(14):3425\u201331.","journal-title":"Clin Cancer Res"},{"key":"805_CR192","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1146\/annurev.immunol.021908.132706","volume":"27","author":"JE Smith-Garvin","year":"2009","unstructured":"Smith-Garvin JE, Koretzky GA, Jordan. M S.T cell activation. Annu Rev Immunol. 2009;27:591\u2013619.","journal-title":"Annu Rev Immunol"},{"key":"805_CR193","doi-asserted-by":"crossref","unstructured":"Zhang Z, Yang N, Lu H, Chen Y, Xu L, Wang Z et al. Improved antitumor effects elicited by an oncolytic HSV-1 expressing a novel B7H3nb\/CD3 BsAb.Cancer Lett,2024, 588: 216760.","DOI":"10.1016\/j.canlet.2024.216760"},{"key":"805_CR194","doi-asserted-by":"crossref","unstructured":"Jin J, Wang R, Yang J, Hu H, Wang D, Cai L et al. Bispecific antibody expressed by an oncolytic herpes simplex virus type 2 can transform heterologous T cells into uniform tumor killer cells.Hum Gene Ther,2022, 33 (11\u201312): 649\u201363.","DOI":"10.1089\/hum.2021.277"},{"key":"805_CR195","doi-asserted-by":"crossref","unstructured":"Vivier E, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G et al. Innate Lymphoid Cells: 10 Years On.Cell,2018, 174 (5): 1054\u201366.","DOI":"10.1016\/j.cell.2018.07.017"},{"key":"805_CR196","doi-asserted-by":"crossref","unstructured":"Gu X, Gao C, Su X, Zhu Y, Fang Q, Yu J et al. Targeting BATF2-RGS2 axis reduces T-cell exhaustion and restores anti-tumor immunity.Mol Cancer,2025, 24 (1): 157.","DOI":"10.1186\/s12943-025-02387-7"},{"key":"805_CR197","doi-asserted-by":"crossref","unstructured":"Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M et al. Understanding the tumor immune microenvironment (TIME) for effective therapy.Nat Med,2018, 24 (5): 541\u201350.","DOI":"10.1038\/s41591-018-0014-x"},{"key":"805_CR198","doi-asserted-by":"crossref","unstructured":"Ma K, Xu Y, Cheng H, Tang K, Ma J. Huang B.T cell-based cancer immunotherapy: opportunities and challenges.Sci Bull (Beijing),2025, 70 (11): 1872\u201390.","DOI":"10.1016\/j.scib.2025.03.054"},{"key":"805_CR199","doi-asserted-by":"crossref","unstructured":"Nikolic I, Cursons J, Shields B, Chappaz S, Sudholz H, Meng X et al. Enhancing anti-tumor immunity of natural killer cells through targeting IL-15R signaling.Cancer Cell,2025, 43 (11): 2034\u201350.","DOI":"10.1016\/j.ccell.2025.05.011"},{"key":"805_CR200","doi-asserted-by":"crossref","unstructured":"Sun Y, Wang Q, Jiang Y, He J, Jia D, Luo M et al. Lactobacillus intestinalis facilitates tumor-derived CCL5 to recruit dendritic cell and suppress colorectal tumorigenesis.Gut Microbes,2025, 17 (1): 2449111.","DOI":"10.1080\/19490976.2024.2449111"},{"key":"805_CR201","doi-asserted-by":"crossref","unstructured":"Rosenberg SA, Restifo NP. .Adoptive cell transfer as personalized immunotherapy for human cancer.Science,2015, 348 (6230): 62\u20138.","DOI":"10.1126\/science.aaa4967"},{"key":"805_CR202","doi-asserted-by":"crossref","unstructured":"Falg\u00e0s A, L\u00e1zaro-Gorines R, Zanetti SR, Rubio-P\u00e9rez L, Mart\u00ednez-Moreno A, Vinyoles M et al. A TIM-3-Fc decoy secreted by engineered T cells improves CD19 CAR T-cell therapy in B-cell acute lymphoblastic leukemia.Blood,2025, 145 (22): 2599\u2013613.","DOI":"10.1182\/blood.2024025440"},{"key":"805_CR203","doi-asserted-by":"crossref","unstructured":"Dulery R, Guiraud V, Choquet S, Thieblemont C, Bachy E, Barete S et al. T cell malignancies after CAR T cell therapy in the DESCAR-T registry.Nat Med,2025, 31 (4): 1130\u20133.","DOI":"10.1038\/s41591-024-03458-w"},{"key":"805_CR204","doi-asserted-by":"crossref","unstructured":"Neo SY, Xu S, Chong J, Lam KP, Wu J. Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer.J Immunother Cancer,2023, 11 (4): e006434.","DOI":"10.1136\/jitc-2022-006434"},{"key":"805_CR205","doi-asserted-by":"crossref","unstructured":"Gattinoni L, Speiser DE, Lichterfeld M, Bonini CT. memory stem cells in health and disease.Nat Med,2017, 23 (1): 18\u201327.","DOI":"10.1038\/nm.4241"},{"key":"805_CR206","doi-asserted-by":"crossref","unstructured":"Chohan KL, Siegler EL, Kenderian SSCAR-T. Cell Therapy: the Efficacy and Toxicity Balance.Curr Hematol Malig Rep,2023, 18 (2): 9\u201318.","DOI":"10.1007\/s11899-023-00687-7"},{"key":"805_CR207","doi-asserted-by":"crossref","unstructured":"Baulu E, Gardet C, Chuvin N. Depil S.TCR-engineered T cell therapy in solid tumors: State of the art and perspectives.Sci Adv,2023, 9 (7): eadf3700.","DOI":"10.1126\/sciadv.adf3700"},{"key":"805_CR208","doi-asserted-by":"crossref","unstructured":"Monberg TJ, Borch TH, Svane IM, Donia MTIL, Therapy. Facts Hopes Clin Cancer Res 2023, 29 (17): 3275\u201383.","DOI":"10.1158\/1078-0432.CCR-22-2428"},{"key":"805_CR209","doi-asserted-by":"publisher","first-page":"102665","DOI":"10.1016\/j.ctrv.2023.102665","volume":"122","author":"CM Ying Li","year":"2024","unstructured":"Ying Li CM, Li R, Drew P, Price T, Smith E, Maddern GJ, et al. Clinical application of cytokine-induced killer (CIK) cell therapy in colorectal cancer: Current strategies and future challenges. Cancer Treat Rev. 2024;122:102665.","journal-title":"Cancer Treat Rev"},{"key":"805_CR210","doi-asserted-by":"crossref","unstructured":"Zheng Y, Ma X, Feng S, Zhu H, Chen X, Yu X et al. Dendritic cell vaccine of gliomas: challenges from bench to bed.Front Immunol,2023, 14: 1259562.","DOI":"10.3389\/fimmu.2023.1259562"},{"key":"805_CR211","doi-asserted-by":"crossref","unstructured":"Xie G, Dong H, Liang Y, Ham JD, Rizwan R, Chen J. CAR-NK cells: A promising cellular immunotherapy for cancer.EBioMedicine,2020, 59: 102975.","DOI":"10.1016\/j.ebiom.2020.102975"},{"key":"805_CR212","doi-asserted-by":"crossref","unstructured":"Li N, Geng S, Dong ZZ, Jin Y, Ying H, Li HW et al. A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy.Mol Cancer,2024, 23 (1): 117.","DOI":"10.1186\/s12943-024-02032-9"},{"key":"805_CR213","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol 2018, 15 (1): 47\u201362.","DOI":"10.1038\/nrclinonc.2017.148"},{"issue":"1","key":"805_CR214","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain MC. Antigen Receptor Therapy N Engl J Med. 2018;379(1):64\u201373.","journal-title":"Antigen Receptor Therapy N Engl J Med"},{"key":"805_CR215","doi-asserted-by":"crossref","unstructured":"Liu Y, Tu Y, Yan Z, Xiao J, Zhou B, Liu T et al. CAR T-Cell therapy in chronic myeloid leukemia patients with lymphoid blast crisis: A multicenter clinical analysis.Cancer Lett,2025, 621: 217688.","DOI":"10.1016\/j.canlet.2025.217688"},{"key":"805_CR216","doi-asserted-by":"crossref","unstructured":"Ghidini M, Tomasello G. CAR T-cell therapy in advanced gastro-oesophageal cancer.Lancet,2025, 405 (10494): 2024\u20135.","DOI":"10.1016\/S0140-6736(25)01095-5"},{"key":"805_CR217","doi-asserted-by":"crossref","unstructured":"Sadelain M, Brentjens R. Rivi\u00e8re I.The basic principles of chimeric antigen receptor design.Cancer Discov,2013, 3 (4): 388\u201398.","DOI":"10.1158\/2159-8290.CD-12-0548"},{"key":"805_CR218","doi-asserted-by":"crossref","unstructured":"Fesnak AD, June CH, Levine BL. .Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer 2016, 16 (9): 566\u201381.","DOI":"10.1038\/nrc.2016.97"},{"key":"805_CR219","doi-asserted-by":"crossref","unstructured":"Rakhshandehroo T, Mantri SR, Moravej H, Louis BBV, Salehi Farid A, Munaretto L et al. A CAR enhancer increases the activity and persistence of CAR T cells.Nat Biotechnol,2025, 43 (6): 948\u201359.","DOI":"10.1038\/s41587-024-02339-4"},{"key":"805_CR220","doi-asserted-by":"crossref","unstructured":"Cao Z, Pu C, Jiang X, Han G, Shen X, Wang W et al. Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach.J Immunother Cancer,2025, 13 (5): e011238.","DOI":"10.1136\/jitc-2024-011238"},{"key":"805_CR221","doi-asserted-by":"crossref","unstructured":"Watanabe N, Mo F, Mckenna MK. .Impact of Manufacturing Procedures on CAR T Cell Functionality.Front Immunol,2022, 13: 876339.","DOI":"10.3389\/fimmu.2022.876339"},{"key":"805_CR222","doi-asserted-by":"crossref","unstructured":"Sterner RC, Sterner R. M.CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J 2021, 11 (4): 69.","DOI":"10.1038\/s41408-021-00459-7"},{"key":"805_CR223","doi-asserted-by":"crossref","unstructured":"Nishio N, Diaconu I, Liu H, Cerullo V, Caruana I, Hoyos V et al. Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors.Cancer Res,2014, 74 (18): 5195\u2013205.","DOI":"10.1158\/0008-5472.CAN-14-0697"},{"key":"805_CR224","doi-asserted-by":"crossref","unstructured":"Xu MY, Zeng N, Liu CQ, Sun JX, An Y, Zhang SH et al. Enhanced cellular therapy: revolutionizing adoptive cellular therapy. Exp Hematol Oncol 2024, 13 (1): 47.","DOI":"10.1186\/s40164-024-00506-6"},{"issue":"1","key":"805_CR225","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-024-01625-7","volume":"17","author":"K Ai","year":"2024","unstructured":"Ai K, Liu B, Chen X, Huang C, Yang L, Zhang W, et al. Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies. J Hematol Oncol. 2024;17(1):105.","journal-title":"J Hematol Oncol"},{"key":"805_CR226","doi-asserted-by":"crossref","unstructured":"Wang Y, Jiang C, Zhou H, Han R. Transforming cancer immunotherapy: integration of distinct immune-based approaches as redefined dual immunotherapy with potential third-sensitizer.Exp Hematol Oncol,2025, 14 (1): 114.","DOI":"10.1186\/s40164-025-00705-9"},{"issue":"640","key":"805_CR227","doi-asserted-by":"publisher","first-page":"eabn2231","DOI":"10.1126\/scitranslmed.abn2231","volume":"14","author":"L Evgin","year":"2022","unstructured":"Evgin L, Kottke T, Tonne J, Thompson J, Huff AL, Van Vloten J, et al. Oncolytic virus\u2013mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice. Sci Transl Med. 2022;14(640):eabn2231.","journal-title":"Sci Transl Med"},{"key":"805_CR228","doi-asserted-by":"crossref","unstructured":"Wang G, Zhang Z, Zhong K, Wang Z, Yang N, Tang X et al. CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma.Mol Ther,2023, 31 (1): 134\u201353.","DOI":"10.1016\/j.ymthe.2022.08.021"},{"issue":"559","key":"805_CR229","doi-asserted-by":"publisher","first-page":"eaaz1863","DOI":"10.1126\/scitranslmed.aaz1863","volume":"12","author":"AK Park","year":"2020","unstructured":"Park AK, Fong Y, Kim S-I, Yang J, Murad JP, Lu J, et al. Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors. Sci Transl Med. 2020;12(559):eaaz1863.","journal-title":"Sci Transl Med"},{"key":"805_CR230","doi-asserted-by":"crossref","unstructured":"Dehaven BC, Gupta K, Isaacs SN. .The vaccinia virus A56 protein: a multifunctional transmembrane glycoprotein that anchors two secreted viral proteins.J Gen Virol,2011, 92 (Pt 9): 1971\u201380.","DOI":"10.1099\/vir.0.030460-0"},{"key":"805_CR231","doi-asserted-by":"crossref","unstructured":"Cho E, An MH, Lee YS, Ryu EJ, Lee YR, Park SY et al. Development of chimeric antigen receptor (CAR)-T cells targeting A56 viral protein implanted by oncolytic virus.iScience,2024, 27 (3): 109256.","DOI":"10.1016\/j.isci.2024.109256"},{"issue":"9","key":"805_CR232","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00262-024-03757-8","volume":"73","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Yang N, Xu L, Lu H, Chen Y, Wang Z, et al. Systemic delivery of oncolytic herpes virus using CAR-T cells enhances targeting of antitumor immuno-virotherapy. Cancer Immunol Immunother. 2024;73(9):173.","journal-title":"Cancer Immunol Immunother"},{"key":"805_CR233","doi-asserted-by":"crossref","unstructured":"Evgin L, Huff AL, Wongthida P, Thompson J, Kottke T, Tonne J et al. Oncolytic virus-derived type I interferon restricts CAR T cell therapy.Nat Commun,2020, 11 (1): 3187.","DOI":"10.1038\/s41467-020-17011-z"},{"issue":"1","key":"805_CR234","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40164-022-00291-0","volume":"11","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Liu Z, Wei W, Li Y. TCR engineered T cells for solid tumor immunotherapy. Exp Hematol Oncol. 2022;11(1):38.","journal-title":"Exp Hematol Oncol"},{"key":"805_CR235","doi-asserted-by":"crossref","unstructured":"Sent\u00eds I, Melero JL, Cebria-Xart A, Grzelak M, Soto M, Michel A et al. Spatio-temporal T cell tracking for personalized TCR-T designs in childhood cancer.Ann Oncol,2025, 36 (9): 1096\u2013106.","DOI":"10.1016\/j.annonc.2025.05.530"},{"key":"805_CR236","doi-asserted-by":"crossref","unstructured":"Nguyen KA, Liu Z, Davies JS, Mcintosh CP, Draper LM, Norberg SM et al. CD22 TCR-engineered T cells exert antileukemia cytotoxicity without causing inflammatory responses.Sci Adv,2025, 11 (15): eadq4297.","DOI":"10.1126\/sciadv.adq4297"},{"key":"805_CR237","doi-asserted-by":"crossref","unstructured":"Kuilman T, Schrikkema DS, Gadiot J, Gomez-Eerland R, Bies L, Walker J et al. Enabling next-generation engineered TCR-T therapies based on high-throughput TCR discovery from diagnostic tumor biopsies. Nat Commun 2025, 16 (1): 649.","DOI":"10.1038\/s41467-024-55420-6"},{"key":"805_CR238","doi-asserted-by":"crossref","unstructured":"Lin P, Lin Y, Mai Z, Zheng Y, Zheng J, Zhou Z et al. Targeting cancer with precision: strategical insights into TCR-engineered T cell therapies.Theranostics,2025, 15 (1): 300\u201323.","DOI":"10.7150\/thno.104594"},{"key":"805_CR239","doi-asserted-by":"crossref","unstructured":"Kr\u00e4mer C, Kilian M, Chih YC, Kourtesakis A, Hoffmann DC, Boschert T et al. NLGN4X TCR transgenic T cells to treat gliomas.Neuro Oncol,2024, 26 (2): 266\u201378.","DOI":"10.1093\/neuonc\/noad172"},{"key":"805_CR240","doi-asserted-by":"publisher","first-page":"658753","DOI":"10.3389\/fimmu.2021.658753","volume":"12","author":"Q Zhao","year":"2021","unstructured":"Zhao Q, Jiang Y, Xiang S, Kaboli PJ, Shen J, Zhao Y, et al. Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine. Pros Cons Front Immunol. 2021;12:658753.","journal-title":"Pros Cons Front Immunol"},{"key":"805_CR241","doi-asserted-by":"crossref","unstructured":"Liu Y, Yan X, Zhang F, Zhang X, Tang F, Han Z et al. TCR-T Immunotherapy: The Challenges and Solutions.Front Oncol,2021, 11: 794183.","DOI":"10.3389\/fonc.2021.794183"},{"key":"805_CR242","doi-asserted-by":"crossref","unstructured":"D\u2019angelo SP, Melchiori L, Merchant MS, Bernstein D, Glod J, Kaplan R et al. Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 (c259)T Cells in Synovial Sarcoma.Cancer Discov,2018, 8 (8): 944\u201357.","DOI":"10.1158\/2159-8290.CD-17-1417"},{"key":"805_CR243","doi-asserted-by":"crossref","unstructured":"Shao W, Yao Y, Yang L, Li X, Ge T, Zheng Y et al. Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy. Exp Hematol Oncol 2024, 13 (1): 37.","DOI":"10.1186\/s40164-024-00504-8"},{"issue":"7","key":"805_CR244","doi-asserted-by":"publisher","first-page":"e009443","DOI":"10.1136\/jitc-2024-009443","volume":"12","author":"E Armstrong","year":"2024","unstructured":"Armstrong E, Chiu MK, Foo S, Appleton L, Nenclares P, Patrikeev A, et al. Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T-cell receptor signalling. J Immunother Cancer. 2024;12(7):e009443.","journal-title":"J Immunother Cancer"},{"key":"805_CR245","doi-asserted-by":"crossref","unstructured":"Schober SJ, Thiede M, Gassmann H, Von Ofen AJ, Knoch P, Eck J et al. TCR-transgenic T cells and YB-1-based oncolytic virotherapy improve survival in a preclinical Ewing sarcoma xenograft mouse model.Front Immunol,2024, 15: 1330868.","DOI":"10.3389\/fimmu.2024.1330868"},{"key":"805_CR246","doi-asserted-by":"crossref","unstructured":"Zinovieva M, Ryapolova A, Karabelsky A, Minskaia E. Oncolytic Vesicular Stomatitis Virus: Optimisation Strategies for Anti-Cancer Therapies.Front Biosci (Landmark Ed),2024, 29 (11): 374.","DOI":"10.31083\/j.fbl2911374"},{"key":"805_CR247","doi-asserted-by":"crossref","unstructured":"Melzer MK, Zeitlinger L, Mall S, Steiger K, Schmid RM, Ebert O et al. Enhanced Safety and Efficacy of Oncolytic VSV Therapy by Combination with T Cell Receptor Transgenic T Cells as Carriers.Mol Ther Oncolytics,2019, 12: 26\u201340.","DOI":"10.1016\/j.omto.2018.12.001"},{"key":"805_CR248","doi-asserted-by":"crossref","unstructured":"Medina T, Chesney JA, Kluger HM, Hamid O, Whitman ED, Cusnir M et al. MadsenLong-term efficacy and safety of lifileucel tumor-infiltrating lymphocyte cell therapy in patients with advanced melanoma: a 5-year analysis of the C-144-01 study.J Clin Oncol,2025, 43 (33): 3565\u201372.","DOI":"10.1200\/JCO-25-00765"},{"issue":"10","key":"805_CR249","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1200\/JCO.2005.00.240","volume":"23","author":"ME Dudley","year":"2005","unstructured":"Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23(10):2346\u201357.","journal-title":"J Clin Oncol"},{"key":"805_CR250","unstructured":"Kottschade L, Rodriguez EW, Harding S, Ranjan S, Mcintyre L, Prieto PA et al. Tumor-Infiltrating Lymphocyte Cell Therapy for the Treatment of Advanced Melanoma: From Patient Identification to Posttreatment Management. J Adv Pract Oncol,2025: 1\u201314."},{"key":"805_CR251","doi-asserted-by":"crossref","unstructured":"Kim SH, Lee BR, Kim SM, Kim S, Kim MS, Kim J et al. The identification of effective tumor-suppressing neoantigens using a tumor-reactive TIL TCR-pMHC ternary complex.Exp Mol Med,2024, 56 (6): 1461\u201371.","DOI":"10.1038\/s12276-024-01259-2"},{"key":"805_CR252","doi-asserted-by":"crossref","unstructured":"Gattinoni L, Klebanoff CA, Restifo NP. .Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer 2012, 12 (10): 671\u201384.","DOI":"10.1038\/nrc3322"},{"issue":"1","key":"805_CR253","doi-asserted-by":"publisher","first-page":"uxaf010","DOI":"10.1093\/cei\/uxaf010","volume":"219","author":"CO Madsen","year":"2025","unstructured":"Madsen CO, Velasco Santiago M, Martinenaite E, Holz Borch T, Donia M, Svane IM, et al. Peripheral immune biomarkers associated with response to adoptive cell therapy with tumor infiltrating lymphocytes. Clin Exp Immunol. 2025;219(1):uxaf010.","journal-title":"Clin Exp Immunol"},{"issue":"13","key":"805_CR254","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1158\/1078-0432.CCR-24-4322","volume":"31","author":"EM Verdegaal","year":"2025","unstructured":"Verdegaal EM, Verpoorte AL, Van Der Kooij MK, De Bruin L, Visser M, Van Der Minne CE, et al. Effective TIL therapy for patients with checkpoint-resistant melanoma without lymphodepleting regimens requires IFN\u03b1. Clin Cancer Res. 2025;31(13):2628\u201338.","journal-title":"Clin Cancer Res"},{"key":"805_CR255","doi-asserted-by":"crossref","unstructured":"Sarnaik AA, Hamid O, Khushalani NI, Lewis KD, Medina T, Kluger HM et al. Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.J Clin Oncol,2021, 39 (24): 2656\u201366.","DOI":"10.1200\/JCO.21.00612"},{"issue":"1","key":"805_CR256","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1186\/s12967-024-05826-z","volume":"22","author":"H Hong","year":"2024","unstructured":"Hong H, He Y, Li Y, Shen Y, Qu Y. Clinical trial landscape for TIL therapy: emerging insights and future directions in oncology. J Transl Med. 2024;22(1):1008.","journal-title":"J Transl Med"},{"key":"805_CR257","doi-asserted-by":"crossref","unstructured":"Morales-Molina A, Rodr\u00edguez-Milla M, Gimenez-Sanchez A, Peris\u00e9-Barrios AJ, Garc\u00eda-Castro JC. Virotherapy Increases Tumor-Infiltrating Lymphocytes (TIL) and Decreases their PD-1(+) Subsets in Mouse Immunocompetent Models.Cancers (Basel),2020, 12 (7): 1920.","DOI":"10.3390\/cancers12071920"},{"key":"805_CR258","doi-asserted-by":"crossref","unstructured":"Feist M, Zhu Z, Dai E, Ma C, Liu Z, Giehl E et al. Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy. Cancer Gene Ther 2021, 28 (1\u20132): 98\u2013111.","DOI":"10.1038\/s41417-020-0189-4"},{"key":"805_CR259","doi-asserted-by":"crossref","unstructured":"Ye K, Li F, Wang R, Cen T, Liu S, Zhao Z et al. An armed oncolytic virus enhances the efficacy of tumor-infiltrating lymphocyte therapy by converting tumors to artificial antigen-presenting cells in situ.Mol Ther,2022, 30 (12): 3658\u201376.","DOI":"10.1016\/j.ymthe.2022.06.010"},{"key":"805_CR260","doi-asserted-by":"crossref","unstructured":"Ye K, Yan Y, Su R, Dai Q, Qiao K, Cao Y et al. Oncolytic virus encoding 4-1BBL and IL15 enhances the efficacy of tumor-infiltrating lymphocyte adoptive therapy in HCC.Cancer Gene Ther,2025, 32 (1): 71\u201382.","DOI":"10.1038\/s41417-024-00853-w"},{"key":"805_CR261","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.omto.2020.03.003","volume":"17","author":"V Cervera-Carrascon","year":"2020","unstructured":"Cervera-Carrascon V, Quixabeira DCA, Havunen R, Santos JM, Kutvonen E, Clubb JHA, et al. Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors. Mol Ther Oncolytics. 2020;17:47\u201360.","journal-title":"Mol Ther Oncolytics"},{"issue":"1","key":"805_CR262","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s13046-024-03219-0","volume":"43","author":"E Jirovec","year":"2024","unstructured":"Jirovec E, Quixabeira DCA, Clubb JHA, Pakola SA, Kudling T, Arias V, et al. Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors. J Exp Clin Cancer Res. 2024;43(1):297.","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"805_CR263","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1517\/14712598.2012.675323","volume":"12","author":"G Mesiano","year":"2012","unstructured":"Mesiano G, Todorovic M, Gammaitoni L, Leuci V, Giraudo Diego L, Carnevale-Schianca F, et al. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin Biol Ther. 2012;12(6):673\u201384.","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"805_CR264","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s12013-024-01569-2","volume":"83","author":"Y Li","year":"2025","unstructured":"Li Y, Chen S, Liu S. Immune Effect of Co-Culture of Dendritic Cells and Cytokine-Induced Killer Cells on Prostate Cancer Cells. Cell Biochem Biophys. 2025;83(2):1593\u2013604.","journal-title":"Cell Biochem Biophys"},{"key":"805_CR265","doi-asserted-by":"crossref","unstructured":"Introna M. CIK as therapeutic agents against tumors.J Autoimmun,2017, 85: 32\u201344.","DOI":"10.1016\/j.jaut.2017.06.008"},{"key":"805_CR266","doi-asserted-by":"crossref","unstructured":"Du YN, Wei Q, Zhao LJ, Fan CQ, Guo LR, Ye JF et al. Hydrogel-based co-delivery of CIK cells and oncolytic adenovirus armed with IL12 and IL15 for cancer immunotherapy.Biomed Pharmacother,2022, 151: 113110.","DOI":"10.1016\/j.biopha.2022.113110"},{"key":"805_CR267","doi-asserted-by":"crossref","unstructured":"Banchereau J, Steinman RM. .Dendritic cells and the control of immunity.Nature,1998, 392 (6673): 245\u201352.","DOI":"10.1038\/32588"},{"key":"805_CR268","doi-asserted-by":"crossref","unstructured":"Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012, 12 (4): 265\u201377.","DOI":"10.1038\/nrc3258"},{"key":"805_CR269","doi-asserted-by":"crossref","unstructured":"Dan J, Cai J, Zhong Y, Wang C, Huang S, Zeng Y et al. Oncolytic virus M1 functions as a bifunctional checkpoint inhibitor to enhance the antitumor activity of DC vaccine.Cell Rep Med,2023, 4 (10): 101229.","DOI":"10.1016\/j.xcrm.2023.101229"},{"key":"805_CR270","doi-asserted-by":"crossref","unstructured":"Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL et al. Innate or adaptive immunity? The example of natural killer cells.Science,2011, 331 (6013): 44\u20139.","DOI":"10.1126\/science.1198687"},{"key":"805_CR271","doi-asserted-by":"crossref","unstructured":"Shi Y, Hao D, Qian H, Tao Z. Natural killer cell-based cancer immunotherapy: from basics to clinical trials.Exp Hematol Oncol,2024, 13 (1): 101.","DOI":"10.1186\/s40164-024-00561-z"},{"key":"805_CR272","doi-asserted-by":"crossref","unstructured":"Shang J, Hu S, Wang X. Targeting natural killer cells: from basic biology to clinical application in hematologic malignancies. Exp Hematol Oncol 2024, 13 (1): 21.","DOI":"10.1186\/s40164-024-00481-y"},{"key":"805_CR273","doi-asserted-by":"crossref","unstructured":"Hou J, Xie S, Gao J, Jiang T, Zhu E, Yang X et al. NK cell transfer overcomes resistance to PD-(L)1 therapy in aged mice. Exp Hematol Oncol 2024, 13 (1): 48.","DOI":"10.1186\/s40164-024-00511-9"},{"issue":"6","key":"805_CR274","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020;382(6):545\u201353.","journal-title":"N Engl J Med"},{"key":"805_CR275","doi-asserted-by":"crossref","unstructured":"J\u00f8rgensen LV, Christensen EB, Barnkob MB. Barington T.The clinical landscape of CAR NK cells.Exp Hematol Oncol,2025, 14 (1): 46.","DOI":"10.1186\/s40164-025-00633-8"},{"issue":"1","key":"805_CR276","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s40164-024-00583-7","volume":"13","author":"P Yao","year":"2024","unstructured":"Yao P, Liu YG, Huang G, Hao L, Wang R. The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances. Exp Hematol Oncol. 2024;13(1):118.","journal-title":"Exp Hematol Oncol"},{"key":"805_CR277","doi-asserted-by":"crossref","unstructured":"Ma R, Lu T, Li Z, Teng KY, Mansour AG, Yu M et al. An Oncolytic Virus Expressing IL15\/IL15R\u03b1 Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma.Cancer Res,2021, 81 (13): 3635\u201348.","DOI":"10.1158\/0008-5472.CAN-21-0035"},{"key":"805_CR278","doi-asserted-by":"crossref","unstructured":"Cao M, Wang Z, Lan W, Xiang B, Liao W, Zhou J et al. The roles of tissue resident macrophages in health and cancer.Exp Hematol Oncol,2024, 13 (1): 3.","DOI":"10.1186\/s40164-023-00469-0"},{"key":"805_CR279","doi-asserted-by":"crossref","unstructured":"Li J, Chen P, Ma W. The next frontier in immunotherapy: potential and challenges of CAR-macrophages.Exp Hematol Oncol,2024, 13 (1): 76.","DOI":"10.1186\/s40164-024-00549-9"},{"key":"805_CR280","doi-asserted-by":"crossref","unstructured":"Sahin U. T\u00fcreci \u00d6.Personalized vaccines for cancer immunotherapy.Science,2018, 359 (6382): 1355\u201360.","DOI":"10.1126\/science.aar7112"},{"key":"805_CR281","doi-asserted-by":"crossref","unstructured":"Elliott L, Foster T, Castillo P, Mendez-Gomez H, Sayour. E J Therapeutic mRNA vaccine Appl Oncol Mol Ther 2025, 33 (6): 2610\u20138.","DOI":"10.1016\/j.ymthe.2025.04.044"},{"key":"805_CR282","doi-asserted-by":"crossref","unstructured":"Morisaki S, Onishi H, Morisaki T, Kubo M, Umebayashi M, Tanaka H et al. Dendritic cell-derived exosomes induce monocyte antigen-presentation and immune amplification in neoantigen vaccine therapy.Front Immunol,2025, 16: 1565696.","DOI":"10.3389\/fimmu.2025.1565696"},{"key":"805_CR283","doi-asserted-by":"crossref","unstructured":"Zaidi N, Jaffee EM, Yarchoan M, J N. R C.Recent advances in therapeutic cancer vaccines. Nat Rev Cancer 2025, 25 (7): 517\u201333.","DOI":"10.1038\/s41568-025-00820-z"},{"key":"805_CR284","doi-asserted-by":"crossref","unstructured":"Saxena M, Marron TU, Kodysh J, Finnigan JP Jr., Onkar S, Kaminska A et al. PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting.Cancer Discov,2025, 15 (5): 930\u201347.","DOI":"10.1158\/2159-8290.CD-24-0934"},{"key":"805_CR285","doi-asserted-by":"crossref","unstructured":"Sharma H, Parekh S, Pujari P, Shewale S, Desai S, Bhatla N et al. Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9\u201314 years versus an established quadrivalent HPV vaccine in women aged 15\u201326 years in India: a randomised, active-controlled, multicentre, phase 2\/3 trial.Lancet Oncol,2023, 24 (12): 1321\u201333.","DOI":"10.1016\/S1470-2045(23)00480-1"},{"key":"805_CR286","doi-asserted-by":"crossref","unstructured":"Makoni M. HPV vaccine roll-out in Nigeria and Bangladesh.Lancet Oncol,2023, 24 (12): 1311\u20132.","DOI":"10.1016\/S1470-2045(23)00571-5"},{"key":"805_CR287","doi-asserted-by":"crossref","unstructured":"Burki T. Continued suboptimal HPV vaccine coverage in the USA. Lancet Oncol, 2024;25 (10): 1257.","DOI":"10.1016\/S1470-2045(24)00394-2"},{"key":"805_CR288","doi-asserted-by":"crossref","unstructured":"Cai Z, Su X, Qiu L, Li Z, Li X, Dong X et al. Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion. Mol Cancer, 2021;20 (1): 164.","DOI":"10.1186\/s12943-021-01467-8"},{"key":"805_CR289","doi-asserted-by":"crossref","unstructured":"A Whole Cancer. Cell-Based Vaccine Boosts Cell Killing and Antitumor Immunity. Cancer Discov, 2023;13 (3): Of5.","DOI":"10.1158\/2159-8290.CD-RW2023-008"},{"key":"805_CR290","unstructured":"Huang XF, Ren W, Rollins L, Pittman P, Shah M, Shen L et al. A broadly applicable, personalized heat shock protein-mediated oncolytic tumor vaccine. Cancer Res, 2003;63 (21): 7321\u20139."},{"key":"805_CR291","doi-asserted-by":"crossref","unstructured":"Liu W, Tang H, Li L, Wang X, Yu Z, Li J. Peptide-based therapeutic cancer vaccine: Current trends in clinical application.Cell Prolif,2021, 54 (5): e13025.","DOI":"10.1111\/cpr.13025"},{"key":"805_CR292","doi-asserted-by":"crossref","unstructured":"Guasp P, Reiche C, Sethna Z. Balachandran V P.RNA vaccines for cancer: Principles to practice. Cancer Cell, 2024;42 (7): 1163\u201384.","DOI":"10.1016\/j.ccell.2024.05.005"},{"key":"805_CR293","doi-asserted-by":"crossref","unstructured":"Wang S, Liang B, Wang W, Li L, Feng N, Zhao Y et al. Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. Signal Transduct Target Ther, 2023;8 (1): 149.","DOI":"10.1038\/s41392-023-01408-5"},{"key":"805_CR294","doi-asserted-by":"crossref","unstructured":"Adamik J, Munson PV, Maurer DM, Hartmann FJ, Bendall SC, Arg\u00fcello RJ et al. Immuno-metabolic dendritic cell vaccine signatures associate with overall survival in vaccinated melanoma patients. Nat Commun, 2023;14 (1): 7211.","DOI":"10.1038\/s41467-023-42881-4"},{"key":"805_CR295","doi-asserted-by":"crossref","unstructured":"Yang H, Tian J, Zhao J, Zhao Y, Zhang G. The Application of Newcastle Disease Virus (NDV): Vaccine Vectors and Tumor Therapy.Viruses,2024, 16 (6): 886.","DOI":"10.3390\/v16060886"},{"issue":"10","key":"805_CR296","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.1007\/s00262-023-03486-4","volume":"72","author":"M Grard","year":"2023","unstructured":"Grard M, Idjellidaine M, Arbabian A, Chatelain C, Berland L, Combredet C, et al. Oncolytic attenuated measles virus encoding NY-ESO-1 induces HLA I and II presentation of this tumor antigen by melanoma and dendritic cells. Cancer Immunol Immunother. 2023;72(10):3309\u201322.","journal-title":"Cancer Immunol Immunother"},{"key":"805_CR297","doi-asserted-by":"crossref","unstructured":"Galanis E, Dooley KE, Keith Anderson S, Kurokawa CB, Carrero XW, Uhm JH et al. Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial. Nat Commun, 2024;15 (1): 493.","DOI":"10.1038\/s41467-023-43076-7"},{"issue":"7","key":"805_CR298","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1002\/ijc.32325","volume":"145","author":"I Koske","year":"2019","unstructured":"Koske I, R\u00f6ssler A, Pipperger L, Petersson M, Barnstorf I, Kimpel J, et al. Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment. Int J Cancer. 2019;145(7):1958\u201369.","journal-title":"Int J Cancer"},{"issue":"5","key":"805_CR299","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s40257-018-0359-4","volume":"19","author":"L Cavalcante","year":"2018","unstructured":"Cavalcante L, Chowdhary A, Sosman JA, Chandra S. Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma. Am J Clin Dermatol. 2018;19(5):657\u201370.","journal-title":"Am J Clin Dermatol"},{"issue":"Pt 4","key":"805_CR300","doi-asserted-by":"publisher","first-page":"135541","DOI":"10.1016\/j.ijbiomac.2024.135541","volume":"279","author":"Q Liu","year":"2024","unstructured":"Liu Q, Wu P, Lei J, Bai P, Zhong P, Yang M, et al. Old concepts, new tricks: How peptide vaccines are reshaping cancer immunotherapy?Int. J Biol Macromol. 2024;279(Pt 4):135541.","journal-title":"J Biol Macromol"},{"key":"805_CR301","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jconrel.2024.10.019","volume":"376","author":"J Zhang","year":"2024","unstructured":"Zhang J, Cao J, Wang L, Li S, Meng F, Liang X, et al. Neoantigen sequestrated autophagosomes as therapeutic cancer vaccines. J Control Release. 2024;376:369\u201381.","journal-title":"J Control Release"},{"key":"805_CR302","doi-asserted-by":"crossref","unstructured":"Das K, Belnoue E, Rossi M, Hofer T, Danklmaier S, Nolden T et al. A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity. Nat Commun, 2021;12 (1): 5195.","DOI":"10.1038\/s41467-021-25506-6"},{"issue":"2","key":"805_CR303","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/jcmm.16214","volume":"25","author":"Y Mokhtari","year":"2021","unstructured":"Mokhtari Y, Pourbagheri-Sigaroodi A, Zafari P, Bagheri N, Ghaffari SH. Bashash D.Toll-like receptors (TLRs): An old family of immune receptors with a new face in cancer pathogenesis. J Cell Mol Med. 2021;25(2):639\u201351.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"805_CR304","doi-asserted-by":"publisher","first-page":"2297453","DOI":"10.1080\/21645515.2023.2297453","volume":"20","author":"D Jeon","year":"2024","unstructured":"Jeon D, Hill E. Mcneel D G.Toll-like receptor agonists as cancer vaccine adjuvants. Hum Vaccin Immunother. 2024;20(1):2297453.","journal-title":"Hum Vaccin Immunother"},{"key":"805_CR305","doi-asserted-by":"crossref","unstructured":"Totsch SK, Ishizuka AS, Kang KD, Gary SE, Rocco A, Fan AE et al. Combination Immunotherapy with Vaccine and Oncolytic HSV Virotherapy Is Time Dependent. Mol Cancer Ther, 2024;23 (9): 1273\u201381.","DOI":"10.1158\/1535-7163.MCT-23-0873"},{"key":"805_CR306","doi-asserted-by":"crossref","unstructured":"Atherton MJ, Stephenson KB, Nikota JK, Hu QN, Nguyen A, Wan Y et al. Preclinical development of peptide vaccination combined with oncolytic MG1-E6E7 for HPV-associated cancer. Vaccine, 2018;36 (16): 2181\u201392.","DOI":"10.1016\/j.vaccine.2018.02.070"},{"issue":"1","key":"805_CR307","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s40425-019-0644-7","volume":"7","author":"A Lopes","year":"2019","unstructured":"Lopes A, Feola S, Ligot S, Fusciello M, Vandermeulen G, Pr\u00e9at V, et al. Oncolytic adenovirus drives specific immune response generated by a poly-epitope pDNA vaccine encoding melanoma neoantigens into the tumor site. J Immunother Cancer. 2019;7(1):174.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"805_CR308","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41571-024-00867-1","volume":"21","author":"D Killock","year":"2024","unstructured":"Killock D. Personalized neoantigen mRNA vaccine mitigates melanoma recurrence. Nat Rev Clin Oncol. 2024;21(3):168.","journal-title":"Nat Rev Clin Oncol"},{"key":"805_CR309","doi-asserted-by":"crossref","unstructured":"Trivedi V, Yang C, Klippel K, Yegorov O, Von Roemeling C, Hoang-Minh L et al. mRNA-based precision targeting of neoantigens and tumor-associated antigens in malignant brain tumors. Genome Med, 2024;16 (1): 17.","DOI":"10.1186\/s13073-024-01281-z"},{"key":"805_CR310","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s44178-025-00213-0","volume":"4","author":"EA Adebanjo","year":"2025","unstructured":"Adebanjo EA, Bakare KM, Matthew UO, Fatai LO. Oyekunle D.Novel therapeutic approaches to cancer immunotherapy and mRNA vaccines technology: a review. Holist Integ Oncol. 2025;4:75.","journal-title":"Holist Integ Oncol"},{"issue":"1","key":"805_CR311","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41392-024-01824-1","volume":"9","author":"R Fu","year":"2024","unstructured":"Fu R, Qi R, Xiong H, Lei X, Jiang Y, He J, et al. Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects. Signal Transduct Target Ther. 2024;9(1):118.","journal-title":"Signal Transduct Target Ther"},{"key":"805_CR312","doi-asserted-by":"crossref","unstructured":"Zhang K, Zuo D, Wang Z, Ding J, Xu J, Liu Y et al. Heterologous prime-boost with an mRNA vaccine and an oncolytic virus enhances tumor regression through overcoming intratumoral immune suppression. Cell Rep, 2025; 44 (6): 115745.","DOI":"10.1016\/j.celrep.2025.115745"},{"issue":"13","key":"805_CR313","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.2174\/1389557522666220930154527","volume":"23","author":"X Hao","year":"2023","unstructured":"Hao X, Chen Z, Li H, Wei M, Zuo Z, Su Q. Small-Molecule Drugs in Immunotherapy. Mini Rev Med Chem. 2023;23(13):1341\u201359.","journal-title":"Mini Rev Med Chem"},{"key":"805_CR314","doi-asserted-by":"crossref","unstructured":"Van Der Zanden SY, Luimstra JJ, Neefjes J, Borst J, Ovaa H. Opportunities for Small Molecules in Cancer Immunotherapy. Trends Immunol, 2020;41 (6): 493\u2013511.","DOI":"10.1016\/j.it.2020.04.004"},{"key":"805_CR315","doi-asserted-by":"crossref","unstructured":"Buyel JF. .Plants as sources of natural and recombinant anti-cancer agents. Biotechnol Adv, 2018;36 (2): 506\u201320.","DOI":"10.1016\/j.biotechadv.2018.02.002"},{"key":"805_CR316","doi-asserted-by":"crossref","unstructured":"Wang Y, Wang C, Xia M, Tian Z, Zhou J, Berger JM et al. Engineering small-molecule and protein drugs for targeting bone tumors. Mol Ther, 2024;32 (5): 1219\u201337.","DOI":"10.1016\/j.ymthe.2024.03.001"},{"key":"805_CR317","first-page":"972345","volume":"13","author":"JL Huo","year":"2022","unstructured":"Huo JL, Fu WJ, Liu ZH, Lu N, Jia XQ, Liu. Z S Res Adv Nat Prod tumor immunotherapy Front Immunol. 2022;13:972345.","journal-title":"Z S Res Adv Nat Prod tumor immunotherapy Front Immunol"},{"key":"805_CR318","doi-asserted-by":"crossref","unstructured":"Nuzzo G, Senese G, Gallo C, Albiani F, Romano L, D\u2019ippolito G et al. Antitumor Potential of Immunomodulatory Natural Products. Mar Drugs, 2022;20 (6): 386.","DOI":"10.3390\/md20060386"},{"key":"805_CR319","doi-asserted-by":"crossref","unstructured":"Zhang W, Xu L, Zhang X, Xu J, Jin JO. .Escherichia coli adhesion portion FimH polarizes M2 macrophages to M1 macrophages in tumor microenvironment via toll-like receptor 4. Front Immunol, 2023;14: 1213467.","DOI":"10.3389\/fimmu.2023.1213467"},{"key":"805_CR320","doi-asserted-by":"crossref","unstructured":"Li W, Zhou Q, Lv B, Li N, Bian X, Chen L et al. Ganoderma lucidum Polysaccharide Supplementation Significantly Activates T-Cell-Mediated Antitumor Immunity and Enhances Anti-PD-1 Immunotherapy Efficacy in Colorectal Cancer. J Agric Food Chem, 2024;72 (21): 12072\u201382.","DOI":"10.1021\/acs.jafc.3c08385"},{"key":"805_CR321","doi-asserted-by":"crossref","unstructured":"Tian X, Liang T, Liu Y, Ding G, Zhang F, Ma Z. Extraction, Structural Characterization, and Biological Functions of Lycium Barbarum Polysaccharides: A Review. Biomolecules, 2019;9 (9): 389.","DOI":"10.3390\/biom9090389"},{"key":"805_CR322","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.ijbiomac.2019.09.189","volume":"145","author":"W Li","year":"2020","unstructured":"Li W, Hu X, Wang S, Jiao Z, Sun T, Liu T, et al. Characterization and anti-tumor bioactivity of astragalus polysaccharides by immunomodulation. Int J Biol Macromol. 2020;145:985\u201397.","journal-title":"Int J Biol Macromol"},{"key":"805_CR323","doi-asserted-by":"crossref","unstructured":"Cao M, Yan H, Han X, Weng L, Wei Q, Sun X et al. Ginseng-derived nanoparticles alter macrophage polarization to inhibit melanoma growth. J Immunother Cancer, 2019;7 (1): 326.","DOI":"10.1186\/s40425-019-0817-4"},{"key":"805_CR324","doi-asserted-by":"crossref","unstructured":"Yang Y, Liu Q, Shi X, Zheng Q, Chen L, Sun Y. Advances in plant-derived natural products for antitumor immunotherapy. Arch Pharm Res 2021;44 (11): 987\u20131011.","DOI":"10.1007\/s12272-021-01355-1"},{"key":"805_CR325","doi-asserted-by":"crossref","unstructured":"Fehl DJ, Ahmed M. Curcumin promotes the oncoltyic capacity of vesicular stomatitis virus for the treatment of prostate cancers. Virus Res, 2017;228: 14\u201323.","DOI":"10.1016\/j.virusres.2016.10.020"},{"key":"805_CR326","doi-asserted-by":"crossref","unstructured":"Wang CJ, Xiao CW, You TG, Zheng YX, Gao W, Zhou ZQ et al. Interferon-\u03b1 enhances antitumor activities of oncolytic adenovirus-mediated IL-24 expression in hepatocellular carcinoma. Mol Cancer, 2012;11: 31.","DOI":"10.1186\/1476-4598-11-31"},{"key":"805_CR327","doi-asserted-by":"crossref","unstructured":"Wang Y, Zhang Q, Chen Y, Liang CL, Liu H, Qiu F et al. Antitumor effects of immunity-enhancing traditional Chinese medicine. Biomed Pharmacother, 2020; 121: 109570.","DOI":"10.1016\/j.biopha.2019.109570"},{"issue":"3","key":"805_CR328","doi-asserted-by":"publisher","first-page":"e23677","DOI":"10.1002\/jcla.23677","volume":"35","author":"C Wang","year":"2021","unstructured":"Wang C, Li Q, Xiao B, Fang H, Huang B, Huang F, et al. Luteolin enhances the antitumor efficacy of oncolytic vaccinia virus that harbors IL-24 gene in liver cancer cells. J Clin Lab Anal. 2021;35(3):e23677.","journal-title":"J Clin Lab Anal"},{"key":"805_CR329","doi-asserted-by":"crossref","unstructured":"Golalipour A, Mohammadi A, Hosseinzadeh S, Soltani A, Erfani-Moghadam V. Synergistic cytotoxicity of olive leaf extract-loaded lipid nanocarriers combined with Newcastle disease virus against cervical cancer cells. PLoS One, 2024;19 (8): e0308599.","DOI":"10.1371\/journal.pone.0308599"},{"key":"805_CR330","doi-asserted-by":"crossref","unstructured":"Liu CH, Wong SH, Tai CJ, Tai CJ, Pan YC, Hsu HY et al. Ursolic Acid and Its Nanoparticles Are Potentiators of Oncolytic Measles Virotherapy against Breast Cancer Cells. Cancers (Basel), 2021;13 (1): 136.","DOI":"10.3390\/cancers13010136"},{"key":"805_CR331","doi-asserted-by":"crossref","unstructured":"Bahreyni A, Liu H, Mohamud Y, Xue YC, Fan YM, Zhang YL et al. A combination of genetically engineered oncolytic virus and melittin-CpG for cancer viro-chemo-immunotherapy. BMC Med, 2023;21 (1): 193.","DOI":"10.1186\/s12916-023-02901-y"},{"issue":"1","key":"805_CR332","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13027-023-00521-y","volume":"18","author":"A Ghorbani Alvanegh","year":"2023","unstructured":"Ghorbani Alvanegh A, Mirzaei Nodooshan M, Dorostkar R, Ranjbar R, Jalali Kondori B, Shahriary A, et al. Antiproliferative effects of mesenchymal stem cells carrying Newcastle disease virus and Lactobacillus Casei extract on CT26 Cell line: synergistic effects in cancer therapy. Infect Agent Cancer. 2023;18(1):46.","journal-title":"Infect Agent Cancer"},{"issue":"11","key":"805_CR333","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/s41573-022-00538-9","volume":"21","author":"R Offringa","year":"2022","unstructured":"Offringa R, K\u00f6tzner L, Huck B, Urbahns K. The expanding role for small molecules in immuno-oncology. Nat Rev Drug Discov. 2022;21(11):821\u201340.","journal-title":"Nat Rev Drug Discov"},{"key":"805_CR334","doi-asserted-by":"crossref","unstructured":"Xun Y, Yang H, Kaminska B, You H. Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma.J Hematol Oncol, 2021;14 (1): 176.","DOI":"10.1186\/s13045-021-01191-2"},{"key":"805_CR335","doi-asserted-by":"crossref","unstructured":"Leonard WJ, Lin JX. .Strategies to therapeutically modulate cytokine action. Nat Rev Drug Discov 2023;22 (10): 827\u201354.","DOI":"10.1038\/s41573-023-00746-x"},{"key":"805_CR336","doi-asserted-by":"crossref","unstructured":"Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol, 2004;5 (10): 987\u201395.","DOI":"10.1038\/ni1112"},{"key":"805_CR337","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejpb.2015.03.018","volume":"93","author":"E P\u00e9rez-Herrero","year":"2015","unstructured":"P\u00e9rez-Herrero E, Fern\u00e1ndez-Medarde A. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm. 2015;93:52\u201379.","journal-title":"Eur J Pharm Biopharm"},{"key":"805_CR338","doi-asserted-by":"crossref","unstructured":"Wu Q, Qian W, Sun X, Jiang S. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. J Hematol Oncol, 2022;15 (1): 143.","DOI":"10.1186\/s13045-022-01362-9"},{"key":"805_CR339","doi-asserted-by":"crossref","unstructured":"O\u2019shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity, 2012;36 (4): 542\u201350.","DOI":"10.1016\/j.immuni.2012.03.014"},{"key":"805_CR340","doi-asserted-by":"crossref","unstructured":"Zak J, Pratumchai I, Marro BS, Marquardt KL, Zavareh RB, Lairson LL et al. JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma. Science, 2024;384 (6702): eade8520.","DOI":"10.1126\/science.ade8520"},{"issue":"3","key":"805_CR341","doi-asserted-by":"publisher","first-page":"200826","DOI":"10.1016\/j.omton.2024.200826","volume":"32","author":"K Geoffroy","year":"2024","unstructured":"Geoffroy K, Mullins-Dansereau V, Leclerc-Desaulniers K, Viens M, Bourgeois-Daigneault MC. .Oncolytic vesicular stomatitis virus alone or in combination with JAK inhibitors is effective against ovarian cancer. Mol Ther Oncol. 2024;32(3):200826.","journal-title":"Mol Ther Oncol"},{"key":"805_CR342","doi-asserted-by":"crossref","unstructured":"Nakatake M, Kurosaki H, Nakamura T. Histone deacetylase inhibitor boosts anticancer potential of fusogenic oncolytic vaccinia virus by enhancing cell-cell fusion. Cancer Sci 2024;115 (2): 600\u201310.","DOI":"10.1111\/cas.16032"},{"issue":"2","key":"805_CR343","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.3390\/ijms25021265","volume":"25","author":"T Miao","year":"2024","unstructured":"Miao T, Symonds A, Hickman OJ, Wu D, Wang P, Lemoine N, et al. Inhibition of Bromodomain Proteins Enhances Oncolytic HAdVC5 Replication and Efficacy in Pancreatic Ductal Adenocarcinoma (PDAC) Models. Int J Mol Sci. 2024;25(2):1265.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"805_CR344","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1002\/ijc.25808","volume":"129","author":"X Fu","year":"2011","unstructured":"Fu X, Tao L, Rivera A, Zhang X. Rapamycin enhances the activity of oncolytic herpes simplex virus against tumor cells that are resistant to virus replication. Int J Cancer. 2011;129(6):1503\u201310.","journal-title":"Int J Cancer"},{"key":"805_CR345","doi-asserted-by":"crossref","unstructured":"Bommareddy PK, Aspromonte S, Zloza A, Rabkin SD, Kaufman. H L.MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation. Sci Transl Med 2018;10 (471): eaau0417.","DOI":"10.1126\/scitranslmed.aau0417"},{"key":"805_CR346","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.omto.2022.12.001","volume":"28","author":"T Yamada","year":"2023","unstructured":"Yamada T, Tateishi R, Iwai M, Tanaka M, Ijichi H, Sano M, et al. Overcoming resistance of stroma-rich pancreatic cancer with focal adhesion kinase inhibitor combined with G47\u2206 and immune checkpoint inhibitors. Mol Ther Oncolytics. 2023;28:31\u201343.","journal-title":"Mol Ther Oncolytics"},{"key":"805_CR347","doi-asserted-by":"crossref","unstructured":"Bieri M, Hendrickx R, Bauer M, Yu B, Jetzer T, Dreier B et al. The RGD-binding integrins \u03b1v\u03b26 and \u03b1v\u03b28 are receptors for mouse adenovirus-1 and \u2013\u20093 infection. PLoS Pathog, 2021;17 (12): e1010083.","DOI":"10.1371\/journal.ppat.1010083"},{"key":"805_CR348","doi-asserted-by":"crossref","unstructured":"Joo HY, Baek H, Ahn CS, Park ER, Lee Y, Lee S et al. Development of a novel, high-efficacy oncolytic herpes simplex virus type 1 platform equipped with two distinct retargeting modalities. Mol Ther Oncol 2024; 32 (1): 200778.","DOI":"10.1016\/j.omton.2024.200778"},{"key":"805_CR349","doi-asserted-by":"crossref","unstructured":"Kao CF, Liu CY, Hsieh CL, Carillo KJD, Tzou DL, Wang HC et al. Structural and functional analyses of viral H2 protein of the vaccinia virus entry fusion complex. J Virol, 2023;97 (12): e0134323.","DOI":"10.1128\/jvi.01343-23"},{"key":"805_CR350","doi-asserted-by":"crossref","unstructured":"Relph K, Arif M, Pandha H, Annels N, Simpson GR. .Analysis of ICAM-1 Expression on Bladder Carcinoma Cell Lines and Infectivity and Oncolysis by Coxsackie Virus A21. Methods Mol Biol, 2023;2684: 319\u201327.","DOI":"10.1007\/978-1-0716-3291-8_20"},{"issue":"6","key":"805_CR351","first-page":"1471","volume":"26","author":"GG Au","year":"2005","unstructured":"Au GG, Lindberg AM, Barry RD, Shafren DR. .Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21. Int J Oncol. 2005;26(6):1471\u20136.","journal-title":"Int J Oncol"},{"key":"805_CR352","doi-asserted-by":"crossref","unstructured":"Jung BK, An YH, Jang SH, Jang JJ, Kim S, Jeon JH et al. The artificial amino acid change in the sialic acid-binding domain of the hemagglutinin neuraminidase of newcastle disease virus increases its specificity to HCT 116 colorectal cancer cells and tumor suppression effect. Virol J, 2024;21 (1): 7.","DOI":"10.1186\/s12985-023-02276-9"},{"key":"805_CR353","doi-asserted-by":"crossref","unstructured":"Hyodo A, Seki F, Fukuda K, Tashiro K, Kitai Y, Akahori Y et al. Evolutionary and structural basis of SLAMF1 utilization in morbilliviruses-Implications for host range and cross-species transmission. PLoS Pathog, 2025;21 (6): e1012990.","DOI":"10.1371\/journal.ppat.1012990"},{"issue":"3","key":"805_CR354","first-page":"441","volume":"46","author":"HK Looi","year":"2024","unstructured":"Looi HK, Ngeow YF, Kiew LV, Chang LY. Ong H T.Oncolytic measles virus-induced cell killing in radio-resistant and drug-resistant nasopharyngeal carcinoma. Malays J Pathol. 2024;46(3):441\u201351.","journal-title":"Malays J Pathol"},{"key":"805_CR355","doi-asserted-by":"crossref","unstructured":"Ahmed MM, Okesanya OJ, Ukoaka BM, Ibrahim AM, Lucero-Prisno Iii. D E J V.Vesicular stomatitis virus: insights into pathogenesis, immune evasion, and technological innovations in oncolytic and vaccine development. Viruses, 2024;16 (12): 1933.","DOI":"10.3390\/v16121933"},{"key":"805_CR356","doi-asserted-by":"crossref","unstructured":"Aravamudhan P, Guzman-Cardozo C, Urbanek K, Welsh OL, Konopka-Anstadt JL, Sutherland DM et al. The Murine Neuronal Receptor NgR1 Is Dispensable for Reovirus Pathogenesis. J Virol, 2022;96 (8): e0005522.","DOI":"10.1128\/jvi.00055-22"},{"key":"805_CR357","doi-asserted-by":"crossref","unstructured":"Hou L, Tong X, Pan Y, Shi R, Liu C, Guo J et al. Seneca Valley Virus Enters PK-15 Cells via Caveolae-Mediated Endocytosis and Macropinocytosis Dependent on Low-pH, Dynamin, Rab5, and Rab7. J Virol, 2022;96 (24): e0144622.","DOI":"10.1128\/jvi.01446-22"},{"issue":"1","key":"805_CR358","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41392-022-00921-3","volume":"7","author":"D Song","year":"2022","unstructured":"Song D, Jia X, Liu X, Hu L, Lin K, Xiao T, et al. Identification of the receptor of oncolytic virus M1 as a therapeutic predictor for multiple solid tumors. Signal Transduct Target Ther. 2022;7(1):100.","journal-title":"Signal Transduct Target Ther"},{"key":"805_CR359","doi-asserted-by":"crossref","unstructured":"Li H, Du H, Zhang G, Wu Y, Qiu P, Liu J et al. Curcumin plays a synergistic role in combination with HSV-TK\/GCV in inhibiting growth of murine B16 melanoma cells and melanoma xenografts. PeerJ, 2019;7: e7760.","DOI":"10.7717\/peerj.7760"},{"issue":"9","key":"805_CR360","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1089\/hum.2012.046","volume":"23","author":"V Adam","year":"2012","unstructured":"Adam V, Ekblad M, Sweeney K, M\u00fcller H, Busch KH, Johnsen CT, et al. Synergistic and Selective Cancer Cell Killing Mediated by the Oncolytic Adenoviral Mutant Ad\u2206\u2206 and Dietary Phytochemicals in Prostate Cancer Models. Hum Gene Ther. 2012;23(9):1003\u201315.","journal-title":"Hum Gene Ther"},{"key":"805_CR361","first-page":"1","volume":"3","author":"M Ahmed","year":"2015","unstructured":"Ahmed M, Patel C, Fehl D. The use of oncolytic vesicular stomatitis virus in conjunction with natural products for the treatment of cervical cancers. Adv Tech Biol Med. 2015;3:1\u20136.","journal-title":"Adv Tech Biol Med"},{"key":"805_CR362","doi-asserted-by":"crossref","unstructured":"Ben Yebdri F, Van Grevenynghe J, Tang VA, Goulet ML, Wu JH, Stojdl DF et al. Triptolide-mediated inhibition of interferon signaling enhances vesicular stomatitis virus-based oncolysis. Mol Ther, 2013;21 (11): 2043\u201353.","DOI":"10.1038\/mt.2013.187"},{"key":"805_CR363","doi-asserted-by":"crossref","unstructured":"Liu CH, Tai CJ, Kuo YT, Chang SS, Lin LT. Combination of Oncolytic measles virus and ursolic acid synergistically induces oncolysis of hepatocellular carcinoma cells. Viruses, 2023;15 (6): 1294.","DOI":"10.3390\/v15061294"},{"issue":"2","key":"805_CR364","first-page":"218","volume":"29","author":"DR Kim","year":"2012","unstructured":"Kim DR, Park MY, Lim HJ, Park JS, Cho YJ, Lee SW, et al. Combination therapy of conditionally replicating adenovirus and histone deacetylase inhibitors. Int J Mol Med. 2012;29(2):218\u201324.","journal-title":"Int J Mol Med"},{"key":"805_CR365","doi-asserted-by":"crossref","unstructured":"Wu Y, Chen X, Wang L, Zhou X, Liu Y, Ji D et al. Histone Deacetylase Inhibitor Panobinostat Benefits the Therapeutic Efficacy of Oncolytic Herpes Simplex Virus Combined with PD-1\/PD-L1 Blocking in Glioma and Squamous Cell Carcinoma Models. Viruses, 2022;14 (12): 2796.","DOI":"10.3390\/v14122796"},{"key":"805_CR366","doi-asserted-by":"crossref","unstructured":"Jennings VA, Scott GB, Rose AMS, Scott KJ, Migneco G, Keller B et al. Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition. Mol Ther, 2019;27 (6): 1139\u201352.","DOI":"10.1016\/j.ymthe.2019.04.008"},{"key":"805_CR367","doi-asserted-by":"crossref","unstructured":"Ma J, Li N, Zhao J, Lu J, Ma Y, Zhu Q et al. Histone deacetylase inhibitor trichostatin A enhances the antitumor effect of the oncolytic adenovirus H101 on esophageal squamous cell carcinoma in vitro and in vivo. Oncol Lett, 2017;13 (6): 4868\u201374.","DOI":"10.3892\/ol.2017.6069"},{"key":"805_CR368","doi-asserted-by":"crossref","unstructured":"Mactavish H, Diallo JS, Huang B, Stanford M, Le Boeuf F, De Silva N et al. Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors. PLoS One, 2010;5 (12): e14462.","DOI":"10.1371\/journal.pone.0014462"},{"key":"805_CR369","doi-asserted-by":"crossref","unstructured":"Stanford MM, Barrett JW, Nazarian SH, Werden S, Mcfadden G. Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells. J Virol, 2007;81 (3): 1251\u201360.","DOI":"10.1128\/JVI.01408-06"},{"key":"805_CR370","doi-asserted-by":"crossref","unstructured":"Homicsko K, Lukashev A, Iggo R. D.RAD001 (everolimus) improves the efficacy of replicating adenoviruses that target colon cancer. Cancer Res, 2005;65 (15): 6882\u201390.","DOI":"10.1158\/0008-5472.CAN-05-0309"},{"key":"805_CR371","doi-asserted-by":"crossref","unstructured":"Yoo JY, Swanner J, Otani Y, Nair M, Park F, Banasavadi-Siddegowda Y et al. Oncolytic HSV therapy increases trametinib access to brain tumors and sensitizes them in vivo. Neuro Oncol, 2019;21 (9): 1131\u201340.","DOI":"10.1093\/neuonc\/noz079"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-026-00805-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00805-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00805-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:03:56Z","timestamp":1790298236000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40164-026-00805-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":371,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["805"],"URL":"https:\/\/doi.org\/10.1186\/s40164-026-00805-0","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"99"}}